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Effekten av omega-3 flerumettede fettsyrer på humane kreftceller - 
involverte molekylære mekanismer 
 
Fet fisk og fiskeolje (tran) har i århundrer vært vanlige bestanddeler i norsk kost. På siste 
halvdel av 1800-tallet produserte apotekeren Møller ren tran til medisinsk bruk. Den norske 
professoren Notevarp fant på 1950- og 1960-tallet at fiskeolje inneholdt omega-3 fettsyren (n-
3 PUFA) dokosaheksaensyre (DHA). Han var også den første som beskrev en gunstig effekt 
av n-3 PUFAs på hjerte- og karsykdommer. På 1970-tallet fant legene Bang og Dyerberg at 
Inuitter fra Grønnland hadde lav forekomst av hjerte- og karsykdommer og relaterte det til økt 
innhold av n-3 PUFAs i blodet. Noen epidemiologiske observasjonsstudier har vist at n-3 
PUFAs kan redusere forekomsten av noen krefttyper, blant annet tarmkreft, men resultatene 
har ikke vært entydige. Allikevel har noen kliniske studier, samt mange dyre- og 
cellekultureksperimenter vist at n-3 PUFAs har en vekstinhiberende effekt på noen typer 
kreftceller, men mekanismene bak dette er uklare. Målet med studiene i denne avhandlingen 
har vært å se nærmere på hvordan n-3 PUFAs påvirker veksten av kreftceller og studere 
hvilke mekanismer i cellene som endres ved tilsats av slike fettsyrer i vekstmediet.  
Tilførsel av DHA til humane tarmkreftceller (SW620) i kultur viste at veksten ble 
kraftig redusert i fysiologisk relevante konsentrasjoner, og genekspresjonsanalyser indikerte 
endringer i uttrykket til flere tusen gener involvert i flere ulike biologiske spor. Tilførsel av n-
3 PUFA medførte stress i endoplasmatisk retikulum (ER) og induksjon av ufoldet protein 
respons (UPR). Noen av hovedfunksjonene til ER er protein folding, regulering av 
kalsiumnivå og syntese av lipider og steroler. Forstyrrelse av disse mekanismene, som 
opphopning av ufoldede/feilfoldede proteiner, kan gi ER stress og induksjon av UPR. 
Stressresponsen som kjennetegnes ved økt fosforylering av eukaryot translasjons 
initieringsfaktor 2 Į (eIF2Į-P) ble indusert så tidlig som 3 timer etter DHA-tilførsel. Økt 
eIF2Į-P fører til stopp i protein translasjon, redusert nivå av cellesyklusregulatoren cyclin D 
og cellesyklusarrest, slik at cellene får tid til reparere skader/gjenopprette homeostasen i ER. 
Dersom skadene blir for store, vil imidlertid cellenes dødsmaskineri (apoptose) aktiveres. 
Genekspresjonsesultatene tydet også på endringer i kalsium- og kolesterolhomeostase. 
Tilførsel av DHA til SW620 cellene økte nivået av intracellulært kalsium, sannsynligvis som 
følge av frigjøring av kalsium fra ER og opptak av eksogent kalsium. Den cellulære 
kolesterolsyntesen reguleres av blant annet sterolregulerende elementbindende protein 2 
(SREBP2). Til tross for aktivert SREBP2, ble bare noen av dens målgener oppregulert etter 
DHA-tilførsel. Nysyntese av kolesterol og inkorporering av nysyntetisert kolesterol til 
kolesterylestere ble nedregulert, mens det totale kolesterolnivået var lite påvirket.  
Endringer i kalsiumhomeostase ble ytterligere undersøkt ved å benytte en human 
leukemicellelinje (HL-60) og en mutert klon av HL-60 (E2R2) som er resistent mot det 
kalsiumhomeostase-forstyrrende kjemikalet econazole. Veksten av HL-60 cellene ble kraftig 
redusert ved tilførsel av eikosapentaensyre (EPA), mens veksten av E2R2 cellene bare ble 
moderat påvirket. Genekspresjonsanalyser og induksjon av eIF2Į-P i EPA-behandlede HL-60 
celler indikerte endringer i kalsiumhomeostase og induksjon av UPR. Det ble imidlertid ikke 
påvist ER stress og UPR i E2R2 cellene. Dette tyder på at EPA-responsen i morcellelinjen var 
assosiert med endringer i kalsiumhomeostase og induksjon av UPR.   
Tilførsel av DHA til SW620 cellene indikerte også endringer i uttrykket av flere gener 
og proteiner involvert i regulering av cellesyklus og celledød. Proteinnivået av survivin, livin 
og nukleær faktor kappa B (NFțB) ble redusert, noe som er interessant ettersom disse er 
indusert i ulike krefttyper og er kjente målproteiner for cellegiftbehandling. Hvorvidt n-3 
PUFAs har en plass som supplement til klinisk kreftbehandling beror imidlertid på ytterligere 
forskning innen dette feltet.  
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Abstract 
 
Fatty fish and cod liver oil have been common ingredients in the Norwegian diet for centuries. 
In the latter half of the 1800s the apothecary Møller produced pure cod liver oil for medicinal 
use. In the 1950s and 1960s, the Norwegian Professor Notevarp found that fish oil contained 
the omega-3 polyunsaturated fatty acid (n-3 PUFA) docosahexaenoic acid (DHA). He was 
also the first to describe a beneficial effect of n-3 PUFAs on cardiovascular disease. In the 
1970s, the doctors Bang and Dyerberg found that Greenland Inuits had low incidence of 
cardiovascular disease, and related it to increased n-3 PUFA content in the blood. Some 
epidemiological observational studies have found that n-3 PUFAs may reduce the incidence 
of some cancer types like colon cancer; however, the results have not been consistent. Yet, 
some clinical studies, as well as several animal and cell culture experiments have shown that 
n-3 PUFAs have a growth inhibiting effect on some types of cancers, but the mechanisms 
behind this effect are unclear. The aim of the studies has been to explore the molecular 
mechanisms behind the growth reducing effect of n-3 PUFAs on cancer cells in vitro. 
 Supplementation of DHA to human colon cancer cells (SW620) in culture strongly 
reduced cell growth in physiological relevant concentrations, and gene expression analysis 
indicated changed expression of thousands of genes involved in different biological pathways. 
The DHA treatment resulted in stress in the endoplasmic reticulum (ER) and induction of 
unfolded protein response (UPR). Some of the main functions of the ER are protein folding, 
regulation of calcium levels, as well as synthesis of lipids and sterols. Disruption of any of 
these mechanisms such as accumulation of unfolded/misfolded proteins may result in ER 
stress and induction of UPR. This stress response is characterized by phosphorylation of the 
eukaryotic translation initiation factor 2 Į (eIF2Į-P) which was induced as early as 3 hours 
after DHA administration. Increased eIF2Į-P arrests protein translation, reduces the cell cycle 
regulator cyclin D and induces cell cycle arrest, allowing the cells to repair the damage/restore 
ER homeostasis. However, if damage is too severe, the cell death machinery (apoptosis) will 
be activated.  
 The gene expression results also indicated changes in calcium and cholesterol 
homeostasis. Addition of DHA to SW620 cells increased the intracellular calcium level, 
probably as a result of calcium release from the ER and uptake of exogenous calcium. 
Cellular cholesterol synthesis is regulated by e.g. sterol regulatory element binding protein 2 
(SREBP2). Despite active SREBP2, only some of its target genes were up-regulated by DHA 
supplementation. New synthesis of cholesterol and incorporation of newly synthesized 
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cholesterol into cholesteryl esters were down-regulated, while total cholesterol levels were not 
markedly affected. Changes in calcium homeostasis were further investigated using a human 
leukemia cell line (HL-60) and a mutant HL-60 clone (E2R2) which is resistant towards the 
calcium homeostasis-disturbing chemical econazole. The HL-60 cells were strongly growth 
inhibited by addition of eicosapentaenoic acid (EPA), while the growth of E2R2 cells was 
only moderately affected. Gene expression analysis and induction of eIF2Į-P in EPA-treated 
HL-60 cells indicated changes in calcium homeostasis and induction of UPR in the mother 
cell line, while there was no evidence of ER stress and UPR in E2R2 cells.  
 Administration of DHA to SW620 cells also resulted in changed expression of several 
genes and proteins involved in regulation of cell cycle and cell death. Protein levels of 
survivin, livin and nuclear factor ț B (NFțB) were reduced, which is interesting since they 
are induced in different tumors and are known targetproteins of chemotherapy. Whether n-3 
PUFAs have a place as supplements to clinical cancer treatment depends, however, on further 
research within this field. 
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1. Introduction 
1.1 Fatty acids – structure and function 
Fatty acids (FAs) are important macronutrients. They consist of a hydrocarbon chain of 
variable length, with a carboxyl group (COOH) at one end and a methyl (CH3) group at the 
other end (n- or Ȧ-end) (Fig.1). FAs are classified according to the number of carbons in the 
chain and the type of bond between the carbons. Saturated FAs (SFAs) only have single 
bonds fully saturated with hydrogen atoms, while mono- (MUFA) and polyunsaturated FAs 
(PUFAs) have one or more double bonds, respectively, which are not saturated with hydrogen 
atoms (reviewed in (1-3)). The n-9 MUFA oleic acid (OA, 18:1) is the most common MUFA 
in human diet. Olive oil is rich in OA, but OA is also synthesized in the human body 
(reviewed in (3-5)). The most common PUFAs in nature are those of the n-3 and n-6 families, 
in which the first double bond is positioned either 3 or 6 carbons from the n-end, respectively. 
The n-3 PUFA Į-linoleic acid (ALA, 18:3)  and the n-6 PUFA linoleic acid (LA, 18:2) are 
considered essential fatty acids (EFA) because mammals lack the desaturase enzyme which 
inserts the double bond into the n-3 and n-6 position of PUFAs; hence these PUFAs have to 
be provided by the diet. Plants and vegetables have this desaturase and are therefore 
considered the main source of EFAs in mammals (reviewed in (2, 6)). Dietary sources of n-3 
PUFAs are vegetable oils rich in ALA; canola and flaxseed, leafy green vegetables, walnuts, 
and seafood, fatty fish and fish oil (FO) rich in docosahexaenoic acid (DHA, 22:6) and 
eicosapentaenoic acid (EPA, 20:5) (Fig. 1). N-6 PUFAs mostly originate from plant oils rich 
in LA; corn, safflower and soybean (reviewed in (6)).  
 
 
Figure 1. Structure and nomenclature of DHA, EPA and AA. 
 
ALA and LA can be lengthened (elongated) and further desaturated through a series of 
steps involving elongases and delta-5 (ǻ5)- and ǻ6 desaturases (Fig. 2). ALA can be 
converted to EPA and further to DHA, while LA can be converted to e.g. arachidonic acid 
DHA
EPA
AA
H C3
H C3
H C3
n/ω
n/ω
n/ω
3
3
6
o
o
o
OH
OH
OH
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(AA, 20:4 n-6). The last step in the conversion of both n-3 and n-6 PUFAs is a cycle of ȕ-
oxidation in the peroxisomes. However, n-3 and n-6 PUFAs are not convertible between the 
two classes. These two PUFA classes compete for the same metabolic enzymes. ALA has 
higher affinity for the ǻ6-desaturase compared to LA, but since LA is considered the most 
common dietary PUFA source and is presented in higher amounts than ALA in the Western 
diet, LA will be the more common substrate for the ǻ6-desaturase. Consequently, it is 
important to ensure high enough n-3 PUFA intake, especially through FO, in order to reduce 
LA desaturation and hence the production of AA and eicosanoids derived from this FA 
(reviewed in (4, 6, 7)). However, the activities of ǻ5- and ǻ6 desaturases are known to be 
slow in humans and different factors may influence their activities. Saturated fat and 
cholesterol inhibit their actions, insulin activates the ǻ6 desaturase and the activity of this 
desaturase is reduced with age (reviewed in (8)).  
 
 
 
Figure 2. Desaturation, elongation and ȕ-oxidation of n-3 and n-6 essential FAs. Full names are stated in the 
abbreviations list. 
Linoleic acid
LA (18:2 n-6)
γ-linoleic acid
(18:3 n-6)
Dihomo-γ-linoleic acid
(20:3 n-6)
Arachidonic acid
AA (20:4 n-6)
Docosatetraenoic acid
(22:4 n-6)
Tetracosatetraenoic acid
(24:4 n-6)
Tetracosapentaenoic acid
(24:5 n-6)
Docosapentaenoic acid
(22:5 n-6)
N-6 PUFAs
α-linoleic acid
ALA (18:3 n-3)
Stearidonic acid
(18:4 n-3)
Eicosatetraenoic acid
(20:4 n-3)
Eicosapentaenoic acid
EPA (20:5 n-3)
Docosapentaenoic acid
(22:5 n-3)
Tetracosapentaenoic acid
(24:5 n-3)
Tetracosahexaenoic acid
(24:6 n-3)
Docosahexaenoic acid
DHA (22:6 n-3)
N-3 PUFAs
Δ6 
desaturase
ELOVL5
Δ5 
desaturase
ELOVL2
ELOVL2
Δ6 
desaturase
β-oxidation
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PUFAs are distributed to different degrees in different tissues and organs. The main n-6 
and n-3 PUFAs in cellular membranes are AA and DHA, respectively (reviewed in (9, 10)). 
Of the n-3 PUFAs, DHA is present in all organs, but especially in brain and retina, while 
ALA and EPA are much less present in tissues. Of the n-6 PUFAs, AA is present in most 
tissues and LA is the most common PUFA stored in triacylglycerols (TAG) in adipose tissue 
(reviewed in (9)). The long chain FAs play different roles in cellular homeostasis. They are 
incorporated into membrane phospholipids, act as substrates for energy production through ȕ-
oxidation and serve as energy stores as part of TAGs. They are also involved in modification 
of proteins i.e. through acetylation in addition to being important in modification of gene 
expression (reviewed in (11-13)). The functions of FAs will be further dealt with in chapter 
1.3.  
 
1.2 Recommendations regarding PUFA intake and bioavailability  
The Western diet today shows signs of increased consumption of fat. In the European 
populations, FAs count for as much as 28-42 % of total energy (TE) consumed, compared to 
approximately 20-30 % of TE in the diet of our ancestors (reviewed in (14)). The latest 
recommendations regarding dietary intake of fat and FAs state that the total fat intake should 
be within 20-35 % of TE, as  concluded in the report “Fats and fatty acids in human nutrition”  
from the 2008 expert consultation held by the World Health Organization (WHO) and Food 
and Agriculture Organization of the United Nations (FAO) (15). This recommendation is 
fulfilled in Norway (Table 1) (16). The type of fat consumed has changed towards an increase 
in saturated fat (especially animal fat) and n-6 PUFA rich oils (reviewed in (14)) and in 
Norway the consumed level of SFAs is higher than recommended (16). There has also been a 
rapid (from an evolutionary point of view) increase in consumption of foods rich in n-6 
PUFAs and a decrease in the intake of n-3 PUFAs in Western societies during the past 150 
years. This results in an increased n-6 to n-3 ratio (n-6/n-3), ranging from 10-20/1 compared 
to 1/1 in the ancestral diet (reviewed in (17)) which contained as much as ~5-6 g/day of n-3 
PUFAs with a high EPA and DHA proportion (reviewed in (14)). PUFA consumption by 
Norwegians is just below the lower recommended intake of total PUFAs (n-3 and n-6) (Table 
1). The consumed amount of n-6 PUFAs is above the recommended, however, the intake of n-
3 PUFAs is sufficient according to recommendations (15, 16). An n-3 PUFA intake of 0.5 
g/day correlates with a minimum of recommended fish intake of 2 fish meals per week (30-40 
g/day), one of them oily fish (reviewed in (14)). However, in contrast to the values presented, 
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a national dietary survey in Norway found that mean daily fish intake was as high as 67 g/day 
and intake of long chain n-3 PUFAs was 0.9 g/day, counting for as much as 0.4 % of TE (18). 
Japanese also fulfil the n-3 PUFA recommendations, while Americans consume far too little 
DHA and EPA (Table 1) (16). 
 
 
Table 1. Recommended intake of dietary fat and FAs, and intake consumed in Norway, Japan and USA. Con = 
consumed, Rec = recommended, % = Percent of total energy intake, g = g/day, M = male, F = female. Data 
collected from (15, 16, 19). aTot = LA + ALA + EPA + DHA, bN-3 = ALA + n-3 long chain PUFAs. 
 
An increase in n-3 PUFA intake could be achieved by promoting fish consumption 
and increasing the use of ALA rich oils instead of dressing oils like safflower oil which is rich 
in n-6 PUFAs. Both wild fish and wild plants tend to have higher amounts of n-3 PUFAs than 
their farmed counterparts, hence intake of these should be promoted (reviewed in (14)). 
Industrial food could be prepared using n-3 PUFA rich oils. Feeding farm animals with n-3 
FA-enriched food has resulted in production of eggs and milk with increased n-3 FA content 
and animals and plants can be genetically manipulated to contain more n-3 PUFAs (reviewed 
in (20)). FO supplements such as n-3 PUFA capsules are also an alternative way to increase 
consumption of these FAs. Intake of one 1 g standard FO capsule provides about 300 mg EPA 
and DHA (reviewed in (21)). Cooking methods also needs to be considered since n-3 PUFAs 
are highly oxidable resulting in harmful free radicals. The n-3 PUFA content in cooked fish 
might be reduced by as much as 50% (reviewed in (14)). 
 One way to assess the bioavailability of n-3 PUFAs is to measure their concentrations 
in blood serum. The basal n-3 PUFA concentration in healthy humans was in one study found 
 
Total fat PUFA LA ALA EPA DHA 
M F M F M F M F M F M F 
Con 
Norway 
31.5% 
97.4g 
30.6% 
67.0g 5.7% 5.3% 13.5g 8.8g 1.8g 1.2g 0.41g 0.27g 0.59g 0.40g
Con 
Japan  49.2g 46.2g   12.9g 10.7g 2.0g 1.6g 0.36g 0.31g 0.63g 0.57g
Con 
USA 98.1g 69.4g   17.1g 12.8g 1.7g 1.3g 0.05g 0.04g 0.09g 0.07g
Rec 
intake 20-35% 
Tot 6-11%a 
n-3 0.5-2%b 2.5-9% 
1-2 g 
 0.5% 0.25-2g 
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to be 136 μM EPA and 261 μM DHA when measured in serum. The concentrations increased 
by 129 % and 45 %, to 312 μM and 379 μM, respectively, after ingesting 57 g cooked salmon 
containing 0,7 g DHA and 0.5 g EPA/day for 8 weeks (22). Others have also shown that the 
EPA and DHA levels measured as free fatty acids (FFA) or phospholipids can be increased 
upon supplementation with n-3 PUFAs (9, 23, 24). Blonk et al found that 12 weeks of 
supplementation with 12 FO capsules (300 mg EPA and 200 mg DHA per capsule, in the 
form of ethyl esters) led to as much as 362 % and 69 % increase in EPA and DHA in plasma 
phospholipids, respectively (24). However, there tend to be a saturation level for n-3 PUFAs 
in blood (9, 24). Harris et al found that the DHA and EPA concentrations correlated well 
between plasma and red blood cells, the latter called the “Omega-3 index”. This index is used 
as an n-3 PUFA bioavailability marker and reflects the n-3 PUFA intake during several 
weeks. It is expressed as n-3 PUFA % of total FAs in red blood cells, with 8 % as an optimal 
target level, and 4 % as undesirable, when it comes to cardioprotection (25).  
 
1.3 Lipid metabolism 
1.3.1 Lipogenesis 
The liver and adipose tissue are the major sites of de novo FA biosynthesis, also called 
lipogenesis. Carbons from glucose (or acetate) are incorporated into FAs through a series of 
enzymatic reactions starting with the formation of malonyl-CoA from acetyl-coenzyme A 
(CoA) by acetyl CoA carboxylase (ACC). The multifunctional enzyme FA synthase (FAS) 
then uses malonyl-CoA as a carbon donor, adding two-carbon units to synthesize mainly the 
SFA palmitatic acid (PA, 16:0) (reviewed in (26, 27)). PA can be further lengthened by 
elongation of very long-chain fatty acid (Elovl) enzymes like Elovl6 in the endoplasmic 
reticulum (ER), or desaturated by the ǻ9 stearoyl-CoA desaturaes (SCD), mainly SCD-1, 
thereby achieving the double bond characteristic of MUFAs (reviewed in (26)).  
 
1.3.2 FA uptake, transport, storage and mobilization by lipolysis 
Dietary TAGs are hydrolysed by lingual and pancreatic lipases into monoacylglycerol (MAG) 
and FAs before uptake by enterocytes, reesterification into TAGs and incorporation into 
chylomicrons. In the liver, FAs are incorporated into very low density lipoprotein (VLDL). 
Hence, FAs are transported in the blood as chylomicrons (exogenous FAs), VLDL 
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(endogenous FAs) as well as FFAs bound to albumin. The enzyme lipoprotein lipase (LPL) 
hydrolyzes FAs from chylomicrons and lipoproteins, which are then free to be transported 
into adipocytes for TAG synthesis (reviewed in (28)). However, the mechanisms by which 
FAs are taken up by adipocytes are not fully understood and it is debated whether the uptake 
is diffusion- or protein mediated. The diffusion theory is based on the observation that FAs 
can flip/flop through membranes, while the protein theory considers the action of FA 
translocase (FAT/CD36), FA transport proteins (FATPs) and plasma membrane bound FA 
binding protein (FABPpm) (reviewed in (29)).  
After entering the cell, FAs are bound to FABPs and transported to the ER where acyl-
CoA synthetases (CoAS) activate FAs into fatty acyl-CoA thioesters (reviewed in (30)). 
These are esterified into TAGs by two different pathways. The MAG pathway esterifies FAs 
with MAG to form first diacylglycerol (DAG) and then TAG. This pathway counts for 75-85 
% of synthesized TAG. The glycerol-3-phosphate pathway stepwise acetylates glycerol-3-
phosphate and/or dihydroxyacetone (from glycolysis) to phosphatidic acid which is 
hydrolysed to DAG which is acetylated to TAG (reviewed in (31)). TAGs are stored in lipid 
droplets in the adipocytes, controlled by perilipins. During basal conditions perilipin-1 
protects TAG from cytosolic lipases and promotes TAG storage, while upon increased 
energetic demands it controls mobilization of FAs from TAGs. This process called lipolysis 
yields FFAs and glycerol, and is controlled by the three lipases hormone-sensitive lipase 
(HSL), adipose triglyceride lipase and MAG lipase. The cAMP-dependent protein kinase A 
pathway is the main pathway known to activate lipolysis and HSL (reviewed in (32)). The 
FFAs bind to adipocyte FABP and are transported to the plasma membrane (reviewed in 
(29)). TAG is the main dietary source of FAs and through lipolysis the yield is ~95 g FAs 
from 100 g TAG (reviewed in (31)), counting for as much as 90 % of the fuel reserves in 
adults (reviewed in (33)). 
 
1.3.3 ȕ-oxidation of FAs 
FAs are degraded to produce energy by a multistep process called ȕ-oxidation. This process 
takes place mainly in the mitochondria, but also in peroxisomes. To be ȕ-oxidized in the 
mitochondria, FFAs have to be taken up by the cell and converted to their fatty acyl-CoA 
thioesters as described above. This can be performed by an acyl-CoAS at the outer 
mitochondrial membrane. The inner mitochondrial membrane is impermeable to long chain 
CoA derivatives and therefore carnitine shuttle proteins have to carry these fatty acyl residues 
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across the membrane. In the mitochondrial matrix, the acyl residues are transferred from 
carnitine to CoA, thereby regenerating acyl-CoA thioesters which are used for ȕ-oxidation. 
FAs up to 10 carbons can enter mitochondria independent of carnitine and are activated by 
acyl-CoASs in the mitochondrial matrix (reviewed in (30)).  
There are four enzymatic steps in the ȕ-oxidation spiral. The third step produces 3-
ketoacyl-CoA that in the fourth step is cleaved between the Į- and ȕ carbons (hence it is 
called ȕ-oxidation) to give acetyl-CoA and fatty acyl-CoA shortened by two carbons that can 
then enter the spiral again. The ȕ-oxidation of unsaturated FAs (UFA) in mitochondria 
requires additional enzymes, in order to handle their double bonds (reviewed in (30)). Acetyl-
CoA can be oxidized by the tricarboxylic acid/Krebs cycle to yield energy, used for the 
formation of ketone bodies through ketogenesis, or take part in cholesterol synthesis 
(reviewed in (27)). Both ȕ-oxidation and lipolysis are regulated by the ratio of the hormones 
[glucagon]/[insulin] which again depend on the nutritional state of the animal (reviewed in 
(30)). During mitochondrial ȕ-oxidation, electrons are transferred to, and hence reduce, 
flavin-adenine dinucleotide and nicotinamide-adenine dinucleotide (NAD+) which drives 
adenosine triphosphate (ATP) synthesis by adding electrons to the electron transport chain. 
High energy level results in a high level of malonyl-CoA which inhibits the carnitine shuttle 
protein carnitine palmitoyltransferase I. Hence, ȕ-oxidation increases when the energy and 
malonyl-CoA level is low and the adenosine monophosphate-activated kinase (AMPK) sensor 
of energy level is high. Mitochondrial ȕ-oxidation oxidizes short- to long chain FAs, while 
very long chain FAs are ȕ-oxidized in peroxisomes and Ȧ-oxidized by the cytochrome P450 
system (reviewed in (27)).  
 
1.3.4 Incorporation of FAs into phospholipids of cellular membranes 
FAs are part of the structural backbone of cellular membranes as they are incorporated into 
membrane phospholipids. The levels of SFAs and MUFAs in membranes are relatively 
constant, while the level of n-3 and n-6 PUFAs are influenced by the dietary intake of these 
FAs. This may be a consequence of the inability of higher animals to synthesize these PUFA 
classes de novo. The type of FAs in membrane lipids is important for membrane function. The 
length and number of double bonds in the chain of FAs are important for the fluidity of the 
lipids, with UFAs increasing the fluidity and therefore always occupying the sn-2 position of 
membrane lipids in order to achieve the correct physical properties of membranes (reviewed 
in (34)).  
15 
 
Membranes also contain lipid micro domains such as lipid rafts and caveolae which 
are membrane domains rich in cholesterol, sphingolipids and phospholipids with saturated 
fatty acyl chains. Several membrane receptors, signaling proteins and lipids are found within 
such lipid rafts, making these microdomains important in signal transduction. The caveolae, 
are enriched in the caveolin-1 protein and are, in addition to signal transduction, known to be 
important in endocytosis and cholesterol transport (reviewed in (35)).  
 
1.3.5 Release of membrane bound FAs and eicosanoid synthesis 
PUFAs are released from phospholipids through cleavage by the phospholipase A2 (PLA2) 
enzyme family (Fig. 3). The C20 PUFAs dihomo-Ȗ-LA (DGLA, 20:3 n-6), AA and EPA are 
then further metabolized to eicosanoids which are biologically potent, short-lived, local 
hormone-like lipids (autacoids) that affect inflammatory and immune responses, and are 
important in platelet aggregation, cellular growth and cell differentiation (reviewed in (10)). 
EPA and AA are metabolized by the same enzymes in the three eicosanid synthesis pathways 
(Fig.3); the cyclo-oxygenase (COX), lipoxygenase (LOX) and cytochrome P450 
monooxygenase (CYP) pathways. The COX pathway produces prostaglandins (PGs) and 
thromboxanes (TXs), the LOX pathway gives leukotrienes (LTs), hydroxy FAs (HETEs, 
HEPEs) and hydroperoxy FAs (HPETEs and HPEPEs) and lipoxins (LXs), and the CYP 
pathway yields HETEs, diHETEs and epoxy FAs (EETs) (reviewed in (10, 36)). Eicosanoids 
derived from the n-3 PUFA EPA include the 3-series of PGs and TXs and the 5-series of LTs, 
HEPE and LX. Recently, other EPA- and DHA-derived autacoids have also been identified, 
named E series of resolvins (RvE, EPA-derived through aspirin-modified COX-2 and LOX), 
D series of resolvins (RvD, through DHA-derived aspirin-modified COX-2 or LOX), 
protectins (DHA-derived through leucocyte-mediated pathways) and maresins (DHA-derived 
through macrophage-mediated pathways) which are all anti-inflammatory (reviewed in (36, 
37)). N-6 PUFA AA-derived eicosanoids include the 2-series of PGs and TXs, the 4-series of 
LTs, LXs, EETs, HETEs, diHETEs and aspirin-triggered lipoxin (ATL, through aspirin-
modified COX-2 and LOX) (reviewed in (36)). DGLA-derived eicosanoids include the 1-
series of PGs. The AA-derived eicosanoids are generally considered pro-inflammatory and 
some have been linked to carcinogenesis, while EPA-derived eicosanoids are anti-
inflammatory and may have anti-cancer properties. Therefore the competition between AA 
and EPA for being incorporated to phospholipids will affect the inflammation status. As 
mentioned above, AA is the major PUFA in cellular membranes, but high intake of n-3 
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PUFAs will result in partial replacement of AA in the membrane phospholipids, less AA-
derived eicosanoids and hence reduced inflammation (reviewed in (10)). The dietary n-6/n-3 
ratio may also be important in modulation of the AA-derived eicosanoid synthesis, since the 
capacity of the n-3 PUFAs to suppress the LA to AA conversion depend on the amount of 
both n-3 and n-6 PUFAs in the diet (reviewed in (4, 38)).  
 
 
Figure 3. Biosynthesis of AA- and EPA-derived eicosanoids, including EPA- and DHA-derived autacoids. Full 
names are stated in the abbreviations list. 
 
1.3.6 Regulation of lipid metabolism by PUFAs 
Lipidomics is the “omics” research field of lipids, which includes the use of several different 
techniques for characterization of cellular lipids and the mechanisms by which they affect 
cellular functions (reviewed in (39)). PUFAs and their metabolites are known to affect gene 
expression through direct binding to transcription factor members of the nuclear receptor 
(NR) superfamily, and indirectly through affecting transcription factors like sterol regulatory 
element binding proteins (SREBP) and carbohydrate response element-binding protein 
(ChREBP). FAs are known to bind to and activate the peroxisome proliferator-activated 
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receptors (PPAR) family; PPARĮ, PPARȕ and PPARȖ. PPARs form heterodimers with the 
PUFA-binding retinoid X receptor (RXR) and bind to a PPAR/RXR consensus sequence in 
the promoter region of target genes, especially genes involved in lipid metabolism (reviewed 
in (40)). PPARĮ is a FA sensor regulating FA mobilization and catabolism, all three 
oxidation-systems described above as well as ketogenesis through its regulation of 
mitochondrial 3-hydroxy-3-methylglutaryl coenzyme A synthase (HMG-CoAS) (reviewed in 
(27)).  
The liver X receptors (LXRĮ and LXRȕ) are also targets for FA regulation. LXRs bind 
oxysterols, form heterodimers with RXR, and regulate genes involved in hepatic bile acid 
synthesis. However, UFAs have been shown to antagonize oxysterol activation of LXR 
(reviewed in (13)). LXRs are also important in regulation of cholesterol homeostasis as well 
as lipogenesis through regulation of SREBP1c. PUFAs are known to supress lipogenic gene 
expression and suppress the gene expression, protein maturation and target gene expression of 
SREBP1C thereby reducing FA and TAG synthesis (reviewed in (27)). PUFAs also supress 
lipogenesis through interfering with the nuclear translocation of ChREBP (reviewed in (40)). 
The hepatic nuclear factor 4 (HNF-4Į and HNF-4ȕ) class of NRs binds fatty acyl-CoA and is 
important in regulation of several hepatic genes encoding proteins involved in e.g. lipoprotein 
metabolism and bile acid synthesis. Saturated acyl-CoA stimulates its transcriptional activity, 
while polyunsaturated fatty acyl-CoA inhibits the effects of HNF-4 on gene expression. The 
nuclear factor farnesoid X receptor (FXR) is activated by bile acids; however this activation is 
antagonized by PUFAs. The last known PUFA-binding NR is the retinoic acid-related orphan 
receptor beta, also known to regulate lipid metabolism (reviewed in (40)).  
 
1.3.7 Cholesterol homeostasis
Cholesterol is an important lipid in e.g. maintenance of membrane fluidity and permeability, 
lipid raft formation and transcriptional regulation. It can be synthesized de novo or taken up 
via plasma lipoproteins like low density lipoprotein (LDL). Cholesterol synthesis, uptake, 
storage, transport and catabolism are tightly regulated by NRs like LXR and SREBPs which 
senses the cholesterol level (reviewed in (41)). The synthesis can be induced by SREBP1a and 
SREBP2, the latter known to regulate genes involved in cholesterol synthesis like HMG-CoA 
reductase (HMG-CoAR), the rate limiting enzyme in de novo cholesterol synthesis. In case of 
low cholesterol level, the SREBP cleavage-activating protein (SCAP) senses the low sterol 
level and escorts SREBP from its position in the ER membrane to the Golgi where the site-1 
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and site-2 proteases (S1P and S2P) cleave and activate SREBP. The nuclear SREBP fragment 
translocates to the nucleus and activates transcription of target genes with sterol response 
elements. In case of high cholesterol level, SCAP retains SREBP in the ER membrane 
(reviewed in (42)), hence SREBP-induced expression of genes involved in cholesterol 
synthesis and uptake is suppressed. NRs, especially LXRs, regulate gene expression involved 
in the sterol homeostasis towards storage, transport and catabolism. High cholesterol level 
also facilitates SREBP1c-induced transcription of genes involved in FA synthesis, thereby 
producing oleyl-CoA that is utilized by acyl-CoA:cholesterol acyltransferase (ACAT) in the 
esterification of cholesterol into cholesteryl esters (CE). CEs can be stored in lipid droplets or 
lipoproteins (reviewed in (41)).  
 
1.4 N-3 PUFAs and disease 
Pioneering work exploring the beneficial health effects of n-3 PUFAs was performed by the 
Norwegian professor Notevarp during the 1950s-1960s. A study published by his research 
group as early as in 1961 described the effect of n-3 PUFAs on cardiovascular disease (43). In 
the 1970s, Bang and Dyerberg revealed a connection between high consumption of sea food 
rich in n-3 PUFAs and low cholesterol- and TAG levels among the Greenland Inuit 
populations. They also speculated that these results could explain the low incidence of 
coronary heart disease in this population (44). Later, research has suggested a disease 
preventive effect of n-3 PUFAs, as outlined below.  
N-3 PUFAs may improve dyslipidaemias and lower the plasma levels of TAGs. 
Individuals with established cardiac pathologies have been shown to benefit from n-3 PUFAs 
as they may slightly decrease blood pressure and inhibit the formation of atherosclerotic 
plaques, as well as reduce the risk of sudden death, cardiac arrhythmias and stroke (reviewed 
in (6, 21, 45, 46)). Even if the n-3 PUFA effect on cardiovascular disease has been studied 
extensively, a meta-analysis by Hooper et al found that results considering n-3 fats and 
cardiovascular disease and total mortality were inconsistent (47). However, their report had 
several drawbacks, as reflected by an expert panel report requested from the International 
Society for the Study of Fatty Acids and Lipids (ISSFAL). The authors concluded that the 
evidence regarding the risk-reducing effect of DHA and EPA on cardiovascular disease were 
sufficient at that time (2006) (48). Also, the experts attending the FAO/WHO consultation in 
2008 concluded that there was convincing evidence for decreased risk of coronary heart 
disease when SFAs are replaced by PUFAs (15).  
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Increased consumption of n-3 PUFAs may also be cardio protective in persons with 
diabetes type 2 (reviewed in (49)), and patients with the multifactor disease metabolic 
syndrome (MS) (reviewed in (14)). Observational studies have suggested that higher maternal 
intake of DHA during pregnancy may have positive influence on some foetus developmental 
outcomes (reviewed in (50)). N-3 PUFAs may also possibly prevent different 
neurodegenerative diseases, like modify the risk and progression of Alzheimer’s disease. In 
addition, they may have positive effects on inflammatory diseases like rheumatoid arthritis 
and inflammatory bowel disease (reviewed in (6, 21, 45, 46)). However, the reports on n-3 
PUFAs and the effect on different diseases are not fully conclusive, which is reflected in the 
FAO/WHO report stating that there is a need for further investigation on e.g. the effect of n-3 
PUFAs on diabetes, Alzheimer’s disease and MS (15). 
N-3 PUFAs have been shown to interfere with the catabolic signal transduction 
pathways involved in cancer cachexia, and may possibly have a positive influence on the loss 
of weight and lean body mass in advanced cancer patients (reviewed in (51)). However, there 
is inconsistency between studies reporting on cachexia and n-3 PUFAs, as reviewed in (52). 
Extensive research has also found that n-3 PUFAs may possibly work as chemopreventive 
agents. Some studies have found an increased intake of n-3 PUFAs to reduce the risk and 
incidence of cancers of e.g. colon and breast. However, these results are not consistent; 
several studies have not found such an association (reviewed in (4)) and the FAO/WHO 
report encourage more research to be performed also in this field (15). The possible “anti-
tumor” effect of PUFAs will be further outlined below.  
 
1.4.1 N-3 PUFAs and cancer  
Dietary fats have for a long time been ascribed a role in cancer development (reviewed in (53, 
54)). Early epidemiological studies reported a positive correlation between high dietary fat 
content and e.g. colon cancer risk. However, some of these studies did not consider the 
different types of fats or their FA content, which later epidemiological observational studies 
found to be important when assessing the relationship between dietary fats and cancers, and 
not the total fat per se (reviewed in (4, 55)). Diets rich in FO and n-3 PUFAs have been 
inversely correlated with the incidence of colorectal and breast cancer in some 
epidemiological observational studies, while diets high in animal fat and n-6 PUFAs 
correlated with an increased risk of these cancers (reviewed in (54, 56)). However, results 
from epidemiological studies exploring the relation between PUFAs and cancers have not 
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been consistent. Even so, cell culture and animal experiments have shown that n-3 PUFAs 
display a growth inhibitory effect on cancer cells originating from e.g. colon, breast and 
leukaemia (reviewed in (2, 4, 10, 57-59)). Interestingly, some clinical intervention studies 
have reported increased effect of conventional chemotherapy and normalization of abnormal 
colorectal tissue proliferation upon n-3 PUFA supplementation (60-64). 
 
Epidemiological observational studies  
Epidemiological observational studies have shown divergent results regarding the anti-tumor 
effects of n-3 PUFAs. Some studies have reported an association between increased n-3 
PUFAs or fish intake and reduced risk for cancers of colon, breast and prostate (reviewed in 
(10, 59, 65)). There are several factors that may have influenced the epidemiological data, and 
thereby complicated the interpretation of them, as outlined below.  
The level of n-3 PUFA intake varies between different populations and a high level of 
fish consumption has been correlated with reduced incidence of some cancers. This has been 
reflected in studies from e.g. Japan, a country with relatively low breast cancer risk and 
dietary fat intake, but high consumption of n-3 PUFAs (reviewed in (4, 65)). However, the 
incidence of breast, colon and prostate cancers is now increasing in Japan natives, reflecting a 
more Westernized diet with decreased fish intake and increased dietary n-6 FAs. The breast 
cancer incidence in Japanese women has been shown to increase within one generation when 
migrating to the USA, a country with relatively high breast cancer risk and dietary fat intake, 
as well as low n-3 PUFA consumption (reviewed in (4, 66)). In Alaskan Eskimos and Aleuts 
lower rates of breast, endometrium and prostate cancers were reported. They have a diet with 
a high fat content; however this comes mainly from fish and marine mammals, giving them a 
high intake of n-3 PUFAs. As in Japan, later studies have shown increasing incidence of both 
breast and colon cancers in this population as well, possibly due to urbanization and changed 
dietary habits (reviewed in (4)).  
It may also be difficult to reveal the real daily intake of n-3 PUFAs in population 
studies where the participants are having fish included in the diet as the n-3 PUFA source. 
This may be due to the differences in n-3 PUFA content between different fish species. Also, 
marine and farmed fish may be contaminated with carcinogenic organochlorine pesticides. 
This should be considered in order to avoid introduction of a carcinogenic agent (the 
pesticides) in addition to antineoplastic agents (n-3 PUFAs), since this could possibly 
interfere with the n-3 PUFA effect in a negative way. This is especially important for breast 
and prostate cancer since the incidence of these cancers has been associated with exposure of 
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such pesticides (reviewed in (57)).  How to increase n-3 consumption was outlined in chapter 
1.2. It is also important to mention that several epidemiological observation studies have 
analyzed the intake of n-3 PUFAs independently of the intake of n-6 PUFAs. However, the n-
6/n-3 ratio has been found to be associated with breast cancer risk (reviewed in (10, 65, 66)).  
 
Clinical and intervention studies 
Several epidemiological observation studies, but not that many clinical studies, exploring the 
effect of n-3 PUFAs in human cancers have been performed. However, some clinical studies 
have been published on colon, breast and prostate. Early clinical studies were performed in 
the 1990s by Anti et al (60, 62). In the first study they supplemented high levels of EPA and 
DHA, 4.1 g and 3.6 g respectively, for periods of 2 weeks to 3 months to persons at high risk 
of having colon cancer because of sporadic polyposis of the colon. The intervention resulted 
in increased levels of DHA and EPA, as well as lower level of LA and AA, in the colonic 
mucosa and plasma. Also, the changed proliferation in colonic mucosa reverted to normal 
(62). The same outcome was also found in the second study, using the same type of patients, 
but supplementing with a lower amount of EPA and DHA (2.5 g/day) for 30 days or 6 months 
(60). Even if 2.5 g/day is somewhat higher than the recommendations from the FAO/WHO 
report (15), it is important to note that n-3 PUFA doses lower than 3.0 g/day are considered 
safe (reviewed in (67)).  
 In the nutritional intervention phase II trial by Read et al, a supplement with 0.92 g 
DHA and 2.18 g EPA/day for up to 9 weeks was given advanced colorectal cancer patients 
receiving chemotherapy. They found an increase in body weight and energy level. Plasma 
phospholipid EPA and DHA levels increased, while AA decreased upon the first three weeks 
of the intervention and were then stable until 9 weeks. Even if not significant, there was a 
trend towards improvement of the quality of life measurement for overall well-being, reduced 
diarrhea and fatigue (68).  
 An interesting randomized, double-blind, placebo-controlled clinical trial carried out 
by West et al enrolled patient with familial adenomatous polyposis (FAP) that had underwent 
colectomy and were undergoing endoscopy surveillance. Patients taking enteric-coated EPA 
as FFA 2 g/day for 6 months had reduced polyp number (>20 %) and size (~30 %), as well as 
decreased polyp burden, compared to the placebo group. EPA supplementation also led to a 
significant increase in mucosal EPA content. The EPA treatment was safe and well tolerated 
(44), and the dose was within the FAO/WHO recommendations (Table 1).   
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Bougnoux et al found that breast cancer patients with a higher n-3 PUFA level in 
breast adipose tissue responded better to chemotherapy (higher degree of tumor regression) 
and that DHA level was associated with tumor response (63). In a pilot phase II clinical trial, 
Bougnoux et al reported that DHA improved the outcome of women with breast cancer 
metastasis treated with an anthracycline-based chemotherapy. The dose used was 1.8 g 
DHA/day (which is within the FAO/WHO recommendations (Table 1)). They found the 
combination of chemotherapy and DHA to be safe without adverse effects. Both time to 
progression and overall survival was higher in patients which had a high incorporation of 
DHA into plasma phospholipids. DHA was found to act as a chemosensitiser, increasing the 
effect of chemotherapy (64).  
 Aronson et al reported the findings from a randomized prospective phase II trial in 
which prostate cancer patients undergoing prostatectomy were given either a low-fat or 
Western diet for 4-6 weeks. The low-fat diet contained 15 % calories from fat and an n-6/n-3 
ratio of 2:1, while the Western diet had 40 % of calories from fat and an n-6/n-3 ratio of 15:1. 
Results showed that the prostate cancer proliferation decreased upon intervention in the low-
fat diet group. Also, the n-6 PUFA, TAG and cholesterol levels decreased, while the n-3 
PUFA level increased in the prostate tissue membranes after invention (61).  
   
Animal studies 
Animal studies using mice or rats bearing human cancer xenografts have shown that an n-3 
PUFA-containing diet can slow down growth of different cancers, e.g. colon, breast, prostate 
and lung, as well as suppress the development and growth of carcinogen-induced cancers in 
animals (reviewed in (1, 4, 37)). In one study, Fini et al supplemented the diet of APCMin/+ 
mice (a model for FAP) with 2 different doses of EPA in the form of FFA for 12 weeks. The 
lowest dose contained EPA (2.5 % of diet in g) and corn oil (CO, 4.5 %), while the highest 
contained EPA (5 %) and CO (2.0 %), and the control diet CO (7.0 %). The EPA diets both 
suppressed the number of polyps with over 70 % and the polyp load with over 80%, however, 
EPA 5 % was most effective (69). Bathen et al showed that supplementing the diet of athymic 
mice (implanted with human colon cancer cells) with FO (DHA and EPA 12 % of calories) 
compared to CO (12 % of calories) resulted in tumor growth reduction (70). N-3 PUFAs have 
also been shown to increase the efficacy of radiation therapy and different cancer 
chemotherapy drugs in vivo (reviewed in (57, 71). Hardman et al implanted lung cancer cells 
into mice and co-treated them with doxorubicin chemotherapy and FO (19 % of diet in g) and 
CO (1 %) or CO (20%). They found that FO in combination with chemotherapy significantly 
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reduced growth of cancer xenografts compared to chemotherapy in combination with CO 
(72). Reddy et al introduced rats to the azoxy-methane carcinogen and supplemented their 
diet with different levels of Menhaden oil (MO) containing n-3 FAs and CO. Introduction of 
MO to the diet reduced the incidence of  having colon adenocarcinomas, however, only the 
diet with the highest content of MO (17.6 %) reduced the number of tumors/rat (73). 
Studies showing an anti-tumor effect of n-3 PUFAs may be promising in the search for 
nontoxic alternative cancer therapies or co-treatments, such as combining conventional 
chemotherapy with n-3 PUFAs in order to sensitize cancer cells to lower concentrations of the 
antineoplastic drugs and reduce harmful side effects (reviewed in (57, 74)).  
 
Cell culture studies 
Several cell culture studies have gathered substantial evidence showing that n-3 PUFAs do 
have a growth-inhibiting effect on e.g. colon, breast and prostate cancer cells in vitro. The 
anti-tumor effect of these PUFAs occur through multiple mechanisms (reviewed in (2, 4, 10, 
58, 65, 75)), as described in chapter 1.5. In vitro cell culture studies also show that n-3 PUFAs 
increase the sensitivity of several types of cancer cells to different chemotherapies, affecting 
different molecular mechanisms that inhibit cell growth (reviewed in (74)).  
 
N-3 PUFAs and colon cancer  
Among both sexes in Western populations in 2008, colorectal cancer was the 3rd most 
frequent type of cancer and cause of cancer deaths. Worldwide, the incidence of colorectal 
cancer in 2008 was ~1,235,000 (9.8 % of all cancers) and number of colorectal cancer deaths 
~609,000 (8.1 % of all cancer deaths). Among the new incidences in 2008 about 60 % 
occurred in developed regions (76). In Norway in 2009, 27,520 new cancer incidents were 
reported, and colorectal cancer (2,405 new incidents) was the second and third most frequent 
cause of cancer deaths among women and men, respectively. The cumulative risk of 
developing colon cancer by the age of 75 in the period of 2005-2009 in Norway ,was 3 % 
among males and 2.7 % among females (this means that about 1 in 33 Norwegian men may 
develop this type of cancer before the age of 75). However, there is a trend towards a 
stabilization of the colon cancer incidence in Norway. More people survive and the mortality 
is declining for both men and women in regard to both colon and rectal cancer. This may be 
due to introduction of a new surgery type and preoperative radiation (77). The high incidence 
and mortality of colon cancer, implies the need for more scientific research, concerning the 
prevention and treatment of colon cancer.  
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Some epidemiological case-control and cohort studies have demonstrated an inverse 
association between n-3 PUFAs or fish intake and the risk of developing colorectal cancer. 
Yet, the results are inconsistent, since several studies find no such association. However, 
promising results are emerging from animal and cell culture studies, showing reduced 
incidence and growth of colorectal cancer after n-3 PUFA treatment. Also, n-3 PUFAs have 
been shown to increase sensitivity towards different colon cancer therapies (reviewed in (67, 
78)). Some human intervention studies have also been performed, like the studies by Anti and 
West et al described above. Recently, Cockbain et al published a comprehensive review on n-
3 PUFAs and their role in treatment and prevention of colorectal cancer (37). 
 
1.5 Main mechanisms and biological pathways involved in the anti-tumor 
effect of n-3 PUFAs    
Several different biological mechanisms and pathways have been proposed to explain the 
anti-tumor effects of n-3 PUFAs, as summarized in Fig. 4. Recently it has been suggested that 
certain PUFAs also are capable of enhancing the uptake of anti-cancer drugs and reducing the 
drug efflux in drug-resistant cells, thereby increasing their anti-tumor action (79). Before the 
n-3 PUFAs can be used as chemo preventive agents or as a supplement to existing cancer 
therapies, clarification of the mechanisms involved is needed.  
 
 
 
Figure 4. Summary of main mechanisms and biological pathways involved in the anti-tumor effect of n-3 
PUFAs  
n-3 
PUFAs
3. AA-derived 
eicosanoids
6. ER stress 4. Membrane characteristics
5. Cell cycle
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1.5.1 Lipid peroxidation and antioxidant defense mechanisms 
Long chain n-3 PUFAs, are highly susceptible to lipid peroxidation (LPO) because of their 
double bonds. Hence, their incorporation into phospholipids of cellular membranes may 
sensitize cells to reactive oxygen species (ROS) and thereby induce oxidative stress (reviewed 
in (80)). LPO is known to degrade phospholipids in cellular membranes, thereby changing 
their permeability and fluidity, as well as producing a range of reactive LPO products that 
drives the reaction further (reviewed in (81)).  
The level of antioxidant enzymes may be altered in cancer cells; lower levels of 
superoxide dismutase (SOD), glutathione peroxidase (GPX) and catalase affect in a negative 
way their ability to handle oxidative stress (reviewed in (82)). LPO products derived from n-3 
PUFAs are involved in the antitumor effects of these PUFAs on some cancer cells, but the 
mechanisms behind this effect is not yet clear (reviewed in (80)). Antioxidants like vitamin E 
and SOD may be able to prevent this effect. Free radicals and LPO can lead to cell death by 
damaging several enzymes, proteins, DNA and depleting ATP levels in the cells. PUFAs have 
the ability of suppressing the antioxidant content of cancer cells, like inhibiting the expression 
of the antioxidant and anti-apoptotic B-cell leukemia/lymphoma 2 (BCl-2), thereby rendering 
the cells even more susceptible to LPO and activation of apoptosis (reviewed in (83)). DHA 
may decrease the intracellular glutathione level in cancer cells (reviewed in (82)). Also, GPX 
was reduced in breast cancer xenografts of mice supplemented with a FO concentrate 
containing n-3 PUFAs. This FO concentrate also potentiated the peroxidizing effect of the 
chemotherapeutic drug doxorubicin which is known for its oxidative stress-inducing effect 
(84). LPO was also involved in the growth reduction of DHA-treated colon cancer cells (85). 
However, a recent review concluded that supplementation of n-3 PUFAs within 0.5-1 g/day or 
slightly higher doses, do not seem to induce a high grade of cytotoxic or pro-carcinogenic 
oxidative stress in normal tissues (86).  
 DHA also incorporates into phospholipids in the mitochondrial membrane of colon 
cancer cells, preferentially cardiolipin (CL), which is important for the integrity of the 
mitochondrial membrane. N-3 PUFA rich CL is easily peroxidized, resulting in altered 
membrane composition and integrity, which together with the resulting CL hydroperoxides 
initiate apoptosis by triggering the release of pro-apoptotic factors, like cytochrome C from 
mitochondria (reviewed in (80, 82)).  
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1.5.2 Eicosanoid production and angiogenesis 
The COX enzyme has two isozymes: COX-1, which is constitutively expressed in several cell 
types, and COX-2, which is induced during inflammation, but not in most normal, non-
inflamed tissues. COX-2 is increased in several cancers, including breast and colon cancer 
(reviewed in (66)). However, n-3 PUFAs may inhibit the induction (87) and reduce the 
expression of COX-2 (69, 88-91). Since EPA competes with AA for COX activity, n-3 
PUFAs will change the type of COX-2-produced products towards less inflammatory and less 
proliferative. This competition also results in reduction of e.g. the pro-tumorigenic AA-
derived PGE2 in favor of the anti-tumorigenic EPA-derived PGE3 (reviewed in (37)). Jia et al 
showed that n-3 FA desaturase-transgenic mice producing n-3 PUFAs from n-6 PUFAs with 
carcinogen-induced colitis-associated colon adenocarcinoma, expressed more PGE3 and less 
PGE2 compared to wild type mice (92). It is important to note that COX inhibitors, like 
celecoxib, may suppress growth of colon cancer in both mice and humans (reviewed in (66, 
80)). N-3 PUFAs can also reduce COX-2 expression by inhibiting nuclear factor kappa B 
(NFțB) resulting in both reduced COX-2 and reduction of NFțB-induced growth promoting 
targets (reviewed in (66)). Even if it is not yet known if RvEs has anti-tumor activity, RvE1 
inhibits NFțB which influences the regulation of colorectal carcinogenesis at an early stage 
(reviewed in (37)).  
There are links between the eicosanoids and angiogenesis, the development of new 
blood vessels, which is critical for tumor growth (reviewed in (93, 94)). DHA and EPA 
reduced growth of HT-29 colon cancer cells in vitro and reduced expression of COX-2, 
vascular endothelial growth factor (VEGF) and reduced PGE2 level. DHA and EPA also 
inhibited phosphorylation of extracellular signal-regulated kinase 1 and 2 (ERK 1 and ERK2) 
and overexpression of hypoxia-inducible-factor 1Į (HIF-1Į). Both DHA and EPA inhibited 
growth of HT-29 xenografts in mice, reduced mircovessel formation and the levels of COX-2, 
PGE2 and VEGF (91). Nitric oxide (NO) is known to increase the activity of prostaglandin 
syntethase and the production of PGE2 (reviewed in (95)). NO is produced by the inducible 
form of NO synthase (iNOS), which have increased activity and/or expression in colon cancer 
in both animal- and human studies and may increase tumor invasiveness, metastatic potential 
and angiogenesis (reviewed in (96, 97)). DHA may decrease iNOS expression, at mRNA and 
protein level, and NO production in colon cancer cells (89, 97). In addition, n-3 PUFAs also 
inhibit angiogenesis by down-regulating angiogenic mediators, such as platelet-derived 
growth factor, NFțB, ȕ-catenin and matrix metalloproteinases (reviewed in (98)).  
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1.5.3 Changes in membrane characteristics and cholesterol synthesis 
Cancer cell membranes are different in composition from noncancerous cell membranes. 
Colonic adenocarcinomas were found to contain more of the SFA stearic acid (SA, 18:0) than 
normal colon mucosa from the same patients, as well as have increased ratios of SA to OA 
and LA. This may result in alterations in lipid rafts structure and protein composition; thereby 
enhancing cancer cell growth and preventing apoptosis ((99) and reviewed in (100)).  
 N-3 PUFAs like DHA and EPA may affect the formation, composition, structure and 
function of lipid rafts such as caveolae, which may affect the physiology of the cell and 
thereby the development of different diseases like cancer. DHA is known to alter the structure 
of cell membranes as well as changing membrane characteristics like permeability and 
fluidity, resulting in changes in membrane based signaling (reviewed in (100)).  
The cholesterol content of cancer cells may be enriched. Some cancer cell types have 
lost the feedback regulation of cholesterol synthesis and absorption; hence they have up-
regulated cholesterol synthesis. The synthesis of SFAs and cholesterol is regulated by FAS 
and HMG-CoAR, respectively and the activity of these enzymes are up-regulated in some 
tumors (reviewed in (100)). EPA may down-regulate the gene expression of FAS (101), and 
EPA and DHA reduced the expression of HMG-CoAR in liver cancer cells (101, 102).  N-3 
PUFAs have been found to down-regulate the transcript (102, 103) and nuclear protein level 
of SREBP1 (104) and SREBP2 in cancer cells (105). Also, a combination of DHA and EPA 
was incorporated into lipid rafts from breast cancer cells in vitro and reduced growth, lipid 
raft sphingomyelin, cholesterol and DAG levels, and interfered with epidermal growth factor 
(EGF) signaling which takes place in lipid rafts (106).  
 
1.5.4 Cell cycle regulation 
The cell cycle ensures proper chromosome duplication and cell division. This happens 
through four different cell cycle phases (Fig. 5); gap 1 (G1), synthesis (S), gap 2 (G2) and 
mitosis (M). Upon cell proliferation signals, cells enter the G1 phase to prepare for DNA 
synthesis/chromosome duplication. During the S phase cells duplicate their chromosomes 
before entering the G2 phase in which they prepare for cell division. During the M phase, 
cells distribute the chromosomes equally to daughter cells. However, most cells in the body 
enters a resting stage called G0 where they are quiescent and do not divide. Deregulation of 
the cell cycle usually leads to activation of apoptosis followed by elimination of the 
deregulated cells from the body. However, if cells overcome their built-in control 
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mechanisms, they may experience a so called “cell cycle disease”, also called cancer, through 
which they continue to divide (reviewed in (107)).   
 In order to maintain correct regulation of the cell cycle, cells have several different 
classes of proteins involved in this regulation. Especially important are cyclin dependent 
kinases (CDKs) which are activated in a cell-cycle stage-specific manner through their 
association with cyclins. CDK activity is also regulated by CDK-inhibitors (CKIs) as well as 
different kinases and phosphatases. Proper progression through the cell cycle is maintained 
through “cell cycle checkpoints,” regulatory pathways ensuring correct order and timing of 
the cell cycle events. If errors like DNA damage occur, checkpoints will delay the cycle until 
the damage is repaired or if not able to repair the damage, lead the cells into apoptosis 
(reviewed in (107)).  
 
G1/S phases and checkpoint 
During G0- and early G1 phases, the cyclin levels are low, CKI levels are high and hence the 
CDK activity is low. Upon extracellular proliferative stimulation through G0 or G1, cells 
enter a new round of cell division. They are committed to perform this cycle when they pass 
the “G1/S transition point”/“restriction (R) point.” Proliferation signals lead to accumulation 
of D-type cyclins which bind CDK4/6, and activation of the CDK4/6-cyclin D complex by the 
CDK-activating kinase (CAK). Active CDK4/6-cyclin D and CDK2-cyclin E complexes 
phosphorylate the retinoblastoma protein (Rb), leaving members of the E2F protein family 
free and active to stimulate the transcription of genes whose products are important for S-
phase entry. The CDK2-Cylin E complex also induces degradation of inhibitory factors like 
the CDK interacting protein/ kinase inhibitory protein (CIP/KIP) family member p27. In case 
of defective DNA, absence of appropriate mitogenic signals or presence of anti-proliferative 
signals, the G1/S checkpoint is activated. The CKI families inhibitor of CDK4 (INK4; p15, 
p16, p18 and p19) and CIP/KIP (p21, p27 and p57) serve as effectors at this checkpoint by 
inhibiting CDKs and preventing cell cycle progression. When the level of proteins required 
for S phase entry is adequately high, tightly controlled chromosome replication is initiated. 
Progression through the S phase is regulated by the CDK2-cyclinA complex, which 
phosphorylates components of the DNA replication machinery and thereby initiating DNA 
replication (reviewed in (107)). 
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G2/M phases and checkpoint 
After completed chromosome duplication, cells enter the G2 phase in which the newly 
divided genetic material is controlled. If DNA damage has occurred, checkpoint pathways 
initiating G2 phase arrest will be activated, leading to CDK1 (CDC2)-inhibition. Potential 
genotoxic stress may activate phosphorylation of human checkpoint kinases 1 and 2 (Chk1 
and Chk2) leading to phosphorylation and thereby inhibition of cell division cycle 25 
(CDC25), a process enhanced by the binding of the CDC25 inhibitor stratifin (SFN/14-3-3ı). 
This blocks CDC25 from dephoshorylating and hence activating CDK1, rendering CDK1 
inactive and preventing mitosis entry. Also, SFN and p21 may bind to the CDK1/cyclin B 
complex, enhancing the G2 arrest. The rate limiting step of mitosis entry is dephosphorylation 
of CDK1/cyclin B by CDC25 homolog B (CDC25B) and CDC25C thereby increasing its 
activity. The M phase tightly controls the division into two daughter cells (reviewed in (107)).    
 
 
Figure 5. Overview of cell cycle regulation and the G1/S and G2/M checkpoints. Full names are stated in the 
abbreviations list.  
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Mutations, overexpression or gene amplification of positive cell cycle regulators (potent 
proto-oncogenes), such as v-myc myelocytomatosis viral oncogene homolog (c-myc), may 
render their activity continuously on and thereby promoting cell proliferation. Overexpression 
of cyclin A, D1 and E, as well as CDK4 and 6 has been found in some human tumors. The 
mutation or deletion and hence inactivation of negative cell cycle regulators (potent tumor 
suppressor genes), such as p53, may destroy their ability to delay/arrest cell cycle progression, 
and hence leave the cell cycle active. Mutations in the p53 gene is found in over 50% of 
human cancers (reviewed in (107)).  
 Several studies have found n-3 PUFAs capable of interfering with cell cycle 
progression in cancer cells, inducing cell cycle arrest in either the G1/S or the G2/M phases 
(88, 104, 108-112) and changing the expression of several genes involved in cell cycle 
regulation at mRNA and/or protein level in different cancer cell types. DHA and/or EPA may 
reduce the protein level of cyclin A (88, 112), cyclin D (89, 113), cyclin E (88, 113), CDK2 
(88, 112), phosphorylated Rb (110, 112) and proliferating cell nuclear antigen (PCNA) (114), 
and increase the protein level of p21 (112). Narayanan et al showed that DHA induced 
extensive changes in gene expression of transcripts involved in e.g. cell cycle regulation, 
including up-regulation of the CKIs p18, p19, p21, p27 and p57 and down-regulation of 
CDK3 in a colon cancer cell line (97, 115). 
 PPAR transcription factors are, in addition to their role in regulation of lipid 
metabolism, also involved in cell proliferation. N-3 PUFAs are known to be PPAR ligands 
which bind to and thereby enhance their transcriptional activity (reviewed in (116)). PPARȖ 
expression may be up-regulated at mRNA level by DHA and EPA (115, 117), and at protein 
level by DHA (118). In order to activate PPARȖ, the DHA concentration has to be >10-30 μM 
(reviewed in (116)).  Several studies have reported PPARȖ to have anti-tumor effects through 
cell cycle regulation, like inducing expression of the tumor-suppressor gene p53 and thereby 
the expression of p21, and induction of apoptosis by inducing expression of the Fas ligand 
and Syndecan 1 among others (reviewed in (116)). Also, the PPARĮ and PPARȖ anti-
inflammatory properties may contribute to suppression of tumor growth (reviewed in (10, 94, 
119)). 
Studies have shown that n-3 PUFAs suppress the expression of protein kinase C (PKC), 
which is known to be mitosis-stimulating (reviewed in (66, 80)), as well as decrease the 
activity of the mitosis-stimulators ras and activator protein 1. The latter ones are oncogenic 
transcription factors known to be frequently activated in cancers (reviewed in (1, 66)). EPA 
and DHA may also reduce the level of the pro-proliferative transcription factor ȕ-catenin by 
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increasing its degradation (89, 90, 120) and reducing its translocation into the nucleus (69, 
120). Decreased level of ȕ-catenin was followed by down-regulation of some of its tumor-
growth involved target genes like c-Met (90) and the inhibitor of apoptosis (IAP) survivin 
(120). 
 
1.5.5 Endoplasmic reticulum homeostasis  
The endoplasmic reticulum (ER) is a metabolic compartment within cells. It has four main 
functions; maintenance of Ca2+ homeostasis, biosynthesis of lipids and sterols, membrane and 
secretory protein synthesis and protein folding. Perturbation of any of these functions causes 
ER stress (reviewed in (121)).  
ER is an important Ca2+ store in eukaryote cells. Within the ER the free [Ca2+] is much 
higher (~1-2 mM) than in the cytosol (0.1 μM). However, the total [Ca2+] in the ER can be 
much higher due to the presence of Ca2+-binding proteins. Ca2+ in- and efflux into/from the 
ER are controlled by the ryanodine receptor (RyR), inositol 1,4,5-triphosphate (IP3) receptor 
(IP3R) and the sarcoplasmic/ER Ca2+ ATPases (SERCA) 1-3. IP3R and RyR are responsible 
for most of the Ca2+ efflux from and SERCA for most of the Ca2+ influx to ER. Ca2+ depletion 
of the ER will lead to inhibition of protein folding and target unfolded proteins for ER 
associated degradation (ERAD), as well as interfering with chaperone function and ER to 
golgi trafficking of proteins (reviewed in (121)). 
The ER membrane is the site for elongation and desaturation of FAs, cholesterol 
metabolism and phospholipid biosynthesis. Depletion of cholesterol or SFAs may increase the 
membrane fluidity, resulting in activation of the SREBP transcription factors that induces 
expression of genes involved in e.g. cholesterol biosynthesis. As mentioned in chapter 1.3.7; 
if the cholesterol level is too high, cholesterol will be esterified with PUFAs by ACAT and 
stored as CEs in lipid droplets in the cell. Sterols may also stimulate degradation of HMG-
CoAR and thereby inhibit cholesterol biosynthesis (reviewed in (121)).  
Within the ER there must be a balance between influx of unfolded proteins, efflux of 
proper folded proteins and targeting of unfolded proteins for proteasomal degradation. This 
retains the protein folding homeostasis in the ER and is added to by a range of chaperones like 
glucose-regulated protein 94 kDa (GRP94), valosin-containing protein (VCP) and several 
different heat shock proteins (Hsps) which bind the hydrophobic surface patches of unfolded 
proteins thereby promoting protein folding and prevent them from binding and aggregating 
with each other. Unfolded or misfolded proteins may be degraded by the proteasomes during 
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ERAD or autophagy (a degradation pathway described below) (reviewed in (121)). Proper 
protein folding and maturation requires a highly oxidizing and Ca2+-rich environment in the 
ER (reviewed in (122)).  
Disturbances in any of the ER functions lead to accumulation of unfolded proteins in 
the ER lumen and thereby induction of ER stress and the common signaling pathway named 
the unfolded protein response (UPR). Different models exist to describe how ER stress is 
sensed. The “competition model” describes how the ER luminal domains of the three ER 
stress sensors double-stranded RNA-activated protein kinase (PKR)-like ER kinase (PERK), 
activating transcription factor 6 (ATF6) and inositol requiring 1 (IRE1) compete with 
unfolded proteins for binding to the heavy chain binding protein/glucose-regulated protein of 
78 kDa (BiP/GRP78) (Fig. 6). BiP is normally bound to the luminal domains of these sensor 
proteins, thereby keeping them in an inactive state. Upon accumulation of unfolded proteins, 
BiP preferentially associates with the unfolded proteins and is thereby sequestered from the 
sensors which then can be activated (reviewed in (121)). During the recent years increased 
knowledge about the sensing of ER stress has emerged, especially on the regulation of IRE1. 
However, much of this work was performed in yeast, but is currently being explored also in 
humans (reviewed in (123)). 
 
PERK 
Dissociation of BiP from PERK leads to its dimerization and autophosphorylation of PERK’s 
cytosolic kinase domain that phosphorylates eukaryotic translation initiation factor 2 alpha 
(eIF2Į-P) (Fig. 6). This leads to inhibition of translation/protein synthesis to relieve the 
protein burden of the ER. However, it induces the transcription of specific genes like 
activating transcription factor 4 (ATF4) (reviewed in (124, 125)). ATF4 regulates genes 
involved in amino acid import, glutathione biosynthesis and resistance to oxidative stress 
(reviewed in (126)). ATF4 induces transcription of genes involved in restoring ER 
homeostasis, a pro-adaptive effect. However, it may also induce a switch from a pro-adaptive 
to a pro-apoptotic effect (reviewed in (127)). Jiang et al found that ATF4 was induced as early 
as 1 h after thapsigargin (TG)-induced ER stress, followed by induction of activating 
transcription factor 3 (ATF3) after 1-3 h, CAAT/enhancer binding protein (C/EBP) 
homologous protein/ growth arrest and DNA damage-153 (CHOP/GADD153) and  growth 
arrest and DNA damage-34 (GADD34) after 6 h. ATF4 was found to be responsible for the 
induction of ATF3 and CHOP, while ATF3 induced GADD34 (128).  
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PERK also phosphorylates the nuclear factor erythroid-2-related factor-2 (Nrf2) 
leading to its dissociation from the inhibitor Kelch-like ECH-associated protein 1 (Keap1). 
Nrf2 translocates to the nucleus where it stimulates gene transcription of genes with 
antioxidant response elements (reviewed in (124)) and thereby plays a pro-survival role 
(reviewed in (126)). 
 
ATF6 
BiP dissociates from ATF6, resulting in the transportation of ATF6 to the Golgi where it is 
cleaved by S1P and S2P (Fig. 6). ATF6 then translocates to the nucleus where it binds to and 
activates target genes with ATF/cAMP response element and ER stress responsive element, 
including several ER chaperones (reviewed in (124)). ATF6 is known to induce the 
transcription of BiP, CHOP and 58 kDa inhibitor of PKR (P58IPK) (reviewed in (126)). X-box 
binding protein 1 (XBP-1) is also induced by ATF6 and their target genes are involved in 
protein folding and degradation in the ER (reviewed in (127)).  
 
IRE1 
Thirdly, the release of BiP from IRE1 leads to dimerization, autophosphorylation and 
activation of its RNAse activity (Fig. 6). IRE1 removes a nucleotide fragment from the XBP-
1 mRNA leading to a spliced mature XBP-1. The precursor and the mature form are both 
translated, but they have different functions. The mature XBP-1 translocates to the nucleus 
and activates UPR target genes (reviewed in (129)), such as proteins involved in protein 
folding and ERAD (reviewed in (127)). The XBP-1 precursor acts as an inhibitor of XBP-1 
signaling, especially important during the recovery phase when ER stress declines and IRE1 
is no longer active (reviewed in (129)). The IRE1 pathway is known to regulate expansion of 
the ER during ER stress (reviewed in (126)).  
 
34 
 
 
Figure 6. Overview of the UPR and key regulators. Full names are stated in the abbreviations list. 
 
Crosstalk between UPR sensor pathways 
There is crosstalk between the three branches of UPR, through XBP-1, which is induced by 
ATF6, activated by IRE1 and induces the expression of the PERK-interacting protein P58IPK, 
the latter one is discussed below (reviewed in (125)). Crosstalk is also reflected through 
CHOP which is induced by ATF4, ATF6 and XBP-1 (reviewed in (130)), and in the temporal 
control of the activation of these three pathways. PERK-dependent eIF2Į-P leading to 
inhibition of protein synthesis, and thereby reducing the protein load on the ER, is the first 
pathway to be activated. This is followed by activation of ATF6 which requires cleavage and 
nuclear translocation in order to induce transcription of ER chaperones. The IRE1 pathway is 
believed to be activated later in UPR. This is because the level of its target XBP-1 is normally 
low, but is induced by ATF6. Therefore, the time schedule could be; translational shutdown, 
chaperone synthesis and at last protein degradation (reviewed in (126)).  
 
ER stress-induced cell cycle arrest, apoptosis and autophagy 
Activation of UPR is known to trigger cell cycle arrest in the G1 phase, as a consequence of 
inhibition of cyclin D translation by eIF2Į-P. This leads to deactivation of cyclin D-dependent 
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CDKs. The cell cycle arrest provides time for restoring ER homeostasis and prevents cells 
from dividing when protein folding is not optimal (reviewed in (131)). 
The adaptive responses induced by UPR are pro-survival. However, prolonged ER 
stress may induce a switch towards cell death (apoptosis is described in chapter 1.5.7). CHOP 
is known to induce the transcription of GADD34 which acts as a feedback loop on the PERK 
pathway in stressed cells, by dephosphorylating eIF2Į and thereby blocking this protecting 
pathway. Also, the induction of P58IPK during UPR is known to repress PERK activity and 
play a role during late UPR. CHOP is also known to induce apoptosis by up-regulation of pro-
apoptotic members like BCl-2 antagonist killer (BAK) and BCl-2 antagonist of cell death 
(BAD), and down-regulation of anti-apoptotic members (BCl-2) of the BCl-2 family. This 
leads to cytochrome c release from mitochondria to cytosol and activation of downstream 
caspase-9 and caspase-3 cascades (reviewed in (127)). CHOP suppresses BCl-2 transcription 
through an interaction with the C/EBP beta (C/EBPȕ) isoform liver inhibitory protein (LIP) 
(reviewed in (130)). Another molecular switch between pro-survival and pro-apoptotic 
function of the PERK pathway is the CHOP-induced tribbles-related protein 3 (TRIB3). 
TRIB3 is proposed to exert negative feedback on CHOP so that cells may adapt to mild ER 
stress. However, TRIB3 inhibits v-Akt murine thymoma viral oncogene homolog 1 (Akt) and 
thereby leads to apoptosis during persistent ER stress (reviewed in (122)).  
IRE1 may recruit tumor-necrosis factor receptor associated factor 2 (TRAF2), thereby 
activating a MAPK cascade through signal-regulating kinase 1 (ASK1), resulting in activation 
of cJUN NH2-terminal kinase (JNK) and p38 MAPK. Activation of JNK can either induce 
autophagy in order to let cells adapt to ER stress, or induce apoptosis when ER stress is 
persistent (reviewed in (122)). Induction of apoptosis requires that JNK activates the pro-
apoptotic BCl-2-interacting protein BIM (BIM) and inhibits BCl-2, thereby leading to 
cytochrome C release and caspase activation. IRE1-signaling is positively regulated by 
interaction with the pro-apoptotic BCl-2 members BAK and BCl-2-associated X protein 
(BAX), and negatively by the anti-apoptotic BAX inhibitor 1 (reviewed in (122, 125)). 
Prolonged ER stress can lead to hyperoxidized ER lumen resulting in H2O2 leakage to 
cytoplasm and ROS production. This hyperoxidation has been linked to the CHOP target ER 
oxidase 1 alpha (ERO1Į). CHOP-induced apoptosis has been shown to involve ERO1Į-
activation of IP3R1, Ca2+ signaling in the cytoplasm and activation of the Ca2+-sensing kinase 
Ca2+/calmodulin-dependent protein kinase II (CaMKII) (reviewed in (130)) 
 Different conditions that induce ER stress can lead to leakage of Ca2+ from the ER to 
the cytosol. This may activate calpain which induces cleavage of procaspase-12, leading to 
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activation of the caspase-9 cascade (reviewed in (127)).  Increased concentration of 
intracellular Ca2+ ([Ca2+]i) may lead to its uptake by the mitochondria. This may activate 
caspase-8 which cleaves B-cell receptor-associated protein 31 (BAP31), an ER membrane-
bound protein, creating a truncated BAP20 product that may promote Ca2+ release from the 
ER. Ca2+ uptake by the mitochondria leads to increased cytochrome C efflux (reviewed in 
(125)).  
 If UPR is not able to restore ER homeostasis, autophagy can be induced to protect 
against the consequences of misfolded/aggregated proteins and damaged organelles. 
Autophagy is a mechanism through which damaged DNA, proteins and organelles are 
sequestered in autophagic vesicles before degradation by lysosomes in order to recycle 
building stones of important macromolecules. It is known as a survival response to growth 
factor or nutrient deprivation, but has also been suggested as a second form of programmed 
cell death (reviewed in (122, 132)). ER stress may induce expansion of the ER membrane as 
well as ER-phagy; the formation of vesicles containing parts of ER, also called ER-containing 
autophagosomes or ERAs. The ERAs may contain damaged ER or ER with protein 
aggregates that have to be degraded. It may also be that ER is degraded in this way in order 
reduce the ER volume upon declined ER stress (133, 134). In ER-stressed cells, autophagy 
can be initiated by PERK, IRE1 and Ca2+-release. PERK-induced eIF2Į-P leads to up-
regulation of autophagy gene 12 (Atg12) which is important in autophagosome formation 
(reviewed in (122)). Upon hypoxia, PERK may also induce the expression of 
Atg8/microtubule-associated protein 1 light chain 3 (LC3) and Atg5 through ATF4 and 
CHOP, respectively (135). Hence, ER stress and autophagy are interlinked.  
 
N-3 PUFAs, ER stress and cancer 
ER stress and UPR are known to be induced in different types of cancers. UPR is important in 
cancer cells in order to induce pro-survival factors such as NFțB, which helps them survive 
and maintain malignancy. UPR factors linked to tumorigenesis include XBP-1, ATF6, eIF2Į-
P, ATF4, CHOP and BiP, as well as Hsps that may be implicated in the adaption of cancer 
cells to different stresses by repairing or degrading damaged proteins. In most normal cells 
UPR is in a quiescent stage. Activation of UPR during early tumorigenesis may induce cell 
cycle arrest in the G1 phase as well as activating p38 mitogen-activated protein kinase 
(MAPK). If UPR induces apoptotic signals at this stage in cancer cells, cells with mutations in 
apoptotic genes may have increased survival. In cancer therapy this can be utilized by 
inducing an overload of misfolded proteins or inhibit the adaptive and anti-apoptotic 
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pathways of UPR. Different cancer drugs targeting the UPR are under development and some 
are being tested in the clinic e.g. different HSP90- and proteasome inhibitors and an active 
component of marijuana called delta (9)-tetrahydrocannabiol (THC) (reviewed in (127)). THC 
was reported to induce cell death in human glioma cells. This was linked to induction of 
autophagy by increased eIF2Į-P and up-regulation of the transcription factors p8, ATF4, 
CHOP and TRIB3, and subsequent TRIB3-dependent inhibition of the AKT/mammalian 
target of rapamycin complex 1 (mTORC1) pathway (136). EPA and/or DHA may decrease 
the phosphorylation and activity of AKT in tumor cells. The AKT/ Phosphoinositide 3-kinase 
(PI3K) signaling pathway is known to be important in the regulation of the cell cycle and 
autophagy, and has been suggested to be constitutively activated in different types of cancers 
(reviewed in (71)). Phosphorylation and hence inactivation of AKT is also associated with 
induction of apoptosis; it hinders it from phosphorylating and hence inhibiting the pro-
apoptotic BAD (137).  
 N-3 PUFAs may decrease the biosynthetic rate of cholesterol (reviewed in (100), as 
outlined in chapter 1.5.3. Changes in cholesterol homeostasis in the ER can induce ER stress 
(reviewed in (121)), and cholesterol depleted cancer cells are known to be prone to induction 
of apoptosis (reviewed in (100)). ER stress may activate SREBP2 (138). However, Zeng et al 
found that ER stress-induced activation of ATF6 may affect cholesterol synthesis by 
interfering with the transcription of SREBP2 target genes (139). Some studies have also 
reported that n-3 PUFAs interfere with Ca2+ homeostasis leading to inhibition of translation 
initiation/eIF2Į-P (113), as well as induction of BiP and CHOP (140). Mechanisms for how 
n-3 PUFAs may increase [Ca2+]i will be outlined below. 
 
1.5.6 Intracellular calcium homeostasis 
Changes in [Ca2+]i are known to interfere with several different signaling pathways and the 
Ca2+ level within cells must therefore be strictly regulated. This regulation includes Ca2+ 
efflux from the ER to the cytosol (commonly through the IP3R), providing a signal for Ca2+ 
influx via the plasma membrane, a process called capacitative or store-operated Ca2+ entry. 
Hence, the Ca2+ level of intracellular Ca2+ stores regulates Ca2+ influx via the plasma 
membrane (reviewed in (141, 142)). However, the mechanism for capacitative influx has been 
largely unknown and under constant research. It is currently believed that it is regulated 
through the ER Ca2+-sensors stromal interaction molecule 1 (STIM1) and STIM2 which may 
lead to the activation of the pore-forming subunit of store-operated Ca2+ release-activated 
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Ca2+ channels (CRAC); Ca2+ release-activated Ca2+ modulator 1 (CRACM1/ORAI) (reviewed 
in (142)). N-3 PUFAs have been reported to release Ca2+ from intracellular Ca2+ stores; 
thereby increasing [Ca2+]i in cancer cells, while the results regarding the ability of n-3 PUFAs 
to stimulate capacitative influx have not been consistent (113, 143).  
 TG increases [Ca2+]i by inhibiting SERCA causing ER Ca2+ depletion and capacitative 
Ca2+ influx (144). The antifungal drug econazole (Ec) also increases the [Ca2+]i in cancer cells 
by inhibiting SERCA and thereby depleting Ca2+ from ER. However, Ec inhibits the TG-
induced capacitative influx in some cancer cells (145, 146), while it may induce capacitative 
Ca2+ influx in other cells (147). Studies have shown that also PUFAs like DHA and EPA may 
decrease TG-induced increase in [Ca2+]i in cancer cells by inhibiting TG-induced capacitative 
influx (113, 148, 149). Mutant cell lines resistant to both Ec and TG have been isolated from 
the human leukemic HL-60 cells. These cells like the E2R2 cells are resistant to ER Ca2+ 
depletion by Ec and have increased capacitative influx. When treated with Ec/TG they 
maintain protein synthesis, probably due to increased content of ribosomal proteins (150).  
 
1.5.7 Apoptosis in cancer cells 
Apoptosis, also called programmed cell death, is tightly regulated by pro- and anti-apoptotic 
factors. Dysregulation may promote cancer. Apoptotic hallmarks include cell shrinkage, 
membrane blebbing and bursting, followed by phagocytosis by surrounding cells or 
packaging into apoptotic bodies. There are two major apoptotic pathways; extrinsic and 
intrinsic. Upon a death signal, the extrinsic pathway is initiated by Fas ligand binding to a Fas 
death receptor. This complex further recruits death domain-containing protein (FADD) and 
procaspase-8 resulting in a protein complex called death inducing signaling complex (DISC) 
in which procaspase-8 is cleaved and activated before it cleaves and activates the effector 
procaspase 3 which drives the apoptotic pathway further (reviewed in (132, 151)). The 
intrinsic pathway is initiated by permeabilization of the mitochondrial membrane thereby 
causing leakage of cytochrome C to the cytosplasm where it binds apoptosis protease-
activating factor 1 (Apaf-1) and procaspase-9 forming an “apoptosome”. Procaspase-9 is 
activated before caspase-3 activation. The last apoptotic steps, packaging into apoptotic 
bodies and phagocytosis by surrounding cells, are the same for the extrinsic and intrinsic 
pathways (reviewed in (151)).  
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Apoptosis and n-3 PUFAs 
Induction of apoptosis is of huge importance in cancer treatment. Several in vitro cell culture 
studies and animal studies have demonstrated that DHA and EPA are able to promote 
apoptosis in cancer cells (reviewed in (75)). The apoptosis inducing effect includes activation 
of different pro-apoptotic factors and down-regulation of anti-apoptotic factors. DHA and/or 
EPA have been found to up-regulate the mRNA level of the procaspases 5, -8, -9, -10 and -13 
(115), as well as increase the cleavage and hence activation of procaspase 3 (137, 152, 153) 
and caspase 8 (152-154). DHA and/or EPA may also induce apoptosis in cancer cells via 
activation of BAD (137) and BH3-interacting domain death agonist (BID) (152) which are 
capable of promoting cytochrome C release, or suppression of the anti-apoptotic BCl-2 family 
members BCl-2 (85, 153-155) and BCl-2 like 1 (BCl2L1/BCl-Xl) (155). DHA also increases 
the expression of the cell proliferator regulator and pro-apoptotic transcription factor c-MYC 
(155), induces cytochrome C release from mitochondria and causes mitochondrial membrane 
depolarization (152). The pro-apoptotic effect of n-3 PUFAs on cancer cells may also involve 
increased activity of neutral sphingomyelinase (156) and formation of ceramide (112, 156). 
NFțB is an important transcription factor in apoptosis regulation. It is usually 
inhibited by inhibitor of țB (IțB) in mammalian cells, but is released and activated upon pro-
apoptotic stimuli. NFțB is constitutively activated in some cancers where it adds to tumor 
growth and cancer cell survival (reviewed in (66, 132)). N-3 PUFAs have been found to 
decrease the expression of NFțB (89, 97), decrease its activity (114) and block the 
degradation of IțB, thereby rendering NFțB inactive (reviewed in (10, 157)).  
 There is also a strong connection between ER stress, autophagy and apoptosis, as 
outlined above (chapter 1.5.5). The effect of ER stress and autophagy may depend on the 
ability of cancer cells to induce apoptosis according to the genetic changes displayed 
(reviewed in (122)).  
 
1.6 Gene expression analysis 
The field of molecular diagnostics includes the elucidation of disease mechanisms to find 
gene-based biomarkers. An important tool in this field, and in molecular biology research, is 
global gene expression analysis using mircroarrays, which allows simultaneously examination 
of the expression of thousands of genes. This tool offers the opportunity to obtain gene 
expression signatures of diseased cells and patient samples, which can be used in the 
exploration of biomarkers and thereby improving early diagnosis and individual treatment. In 
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cancer research this tool can be used for studying changes in gene expression patterns of 
cancer cells compared to normal cells, or in response to drugs, as well as investigating tumor 
classification and cancer progression.  
Different microarray technologies exist in which the probes can be made of cDNA or 
oligonucleotides and are either spotted or synthesized on the microarray surface (reviewed in 
(158)). Different suppliers offer whole genome microarrays, covering the entire transcriptome 
(all the RNA) of different organisms. The Affymetrix GeneChip® System offers microarrays, 
chemicals, instruments and data analysis programs for gene expression analysis. Arrays are 
available for several different organisms, including human. The arrays are produced either as 
focus arrays, with a specific selection of probes, or whole genome arrays, presenting 
transcripts of gene sequences with both known and unknown functions (159). The human full 
genome array from Affymetrix analyzes the expression of about 47,000 transcripts and 
variants. The array fabrication and handling is well standardized which is reflected by low 
technical variability. Variation is although introduced due to e.g. differences in RNA quality 
(reviewed in (160)), which is a critical factor in microarray experiments.  
Gene expression analysis by microarrays is a valuable tool in the field of nutritional 
transcriptomics; the studying of how nutrients may regulate gene expression. Different 
bioactive food components have been reported to affect gene expression in cells (reviewed in 
(161)). Microarrays have also added to the understanding of the possible anti-tumor 
mechanisms of n-3 PUFAs. Scientists have used this technology to outline n-3 PUFA induced 
changes at mRNA level in cell culture and animal experiments, revealing several different 
molecular pathways involved (97, 102, 115).  Hence, it may be that the anti-tumor effect of n-
3 PUFAs involves a combination of different mechanisms, and the elucidation of these 
mechanisms can be aided by the use of microarrays. The requirement for publishing of raw 
data from microarray experiments into public databases also adds to the revealing of 
molecular mechanisms, since the data can be re-analyzed by new approaches in order to find 
additional pathways involved. 
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2. Aims of study  
 
N-3 PUFAs in the form of FO have been a common nutritional supplement in Norway for 
decades. These PUFAs have been associated with positive effects on different diseases like 
cardiovascular disease, some inflammatory conditions and possibly cancer cachexia. Several 
epidemiological observational studies have found that high n-3 PUFA intake reduces the risk 
of some cancers like colon cancer, even if the results are not consistent. These studies are 
supported by an increasing number of clinical studies, as well as animal- and cell culture 
experiments reporting a possible anti-tumor activity of n-3 PUFAs. Several different 
mechanisms have been suggested to be involved in the anti-tumor effect of n-3 PUFAs, but 
the mechanisms have not yet been fully established. N-3 PUFAs may also have a role as 
chemotherapy supplements, but in order to use these PUFAs clinically, the molecular 
mechanisms involved have to be elucidated.  
 
This study aimed at revealing how n-3 PUFAs affect cancer cell growth and in particular 
assessing the molecular mechanisms and cellular pathways contributing to their anti-tumor 
effects by using microarrays for global gene expression profiling. The identification of n-3 
PUFA-induced early responses in cancer cells and the influence of n-3 PUFAs on known 
cancer therapy targets were of special interest.  
 
  
42 
 
3. Summary of papers 
 
Paper I 
DHA induces ER stress and growth arrest in human colon cancer cells: associations with 
cholesterol and calcium homeostasis 
In order to reveal molecular mechanisms behind DHA-induced growth inhibition of cancer 
cells, gene expression profiling was performed using the Affymetrix GeneChip system and 
the Affymetrix Human Genome Focus array. Gene expression results revealed extensive 
changes at transcription level after DHA (70 μM)-supplementation of SW620 colon cancer 
cells for 12, 24 and 48 h. At 12 h of DHA treatment 839 transcripts were up-regulated and 
1066 down-regulated. At 24 h these numbers increased (1157 up-regulated and 1222 down-
regulated), while a markedly fewer genes were differentially expressed at 48 h (288 up-
regulated and 267 down-regulated). Affected transcripts belonged to numerous different 
molecular pathways. Interestingly, several transcripts indicative of ER stress and induction of 
UPR were up-regulated. These included factors from all three UPR branches (ATF6, PERK, 
XBP-1), especially transcripts downstream of PERK; ATF4, ATF3, GADD34, TRIB3 and 
heme oxygenase 1 (HMOX1). This was confirmed by phosphorylation of eIF2Į (eIF2Į –P, 3 
h) and induction ATF4 (6 h) at protein level; indicating that ER stress and UPR were early 
responses to DHA treatment. Tranlational shutdown by eIF2Į –P was suggested by reduced 
cyclin D1. EPA (70 μM) also induced ER stress in SW620 cells, while OA (70 μM) did not. 
Several chaperones and Hsps like HSP70 were highly up-regulated after 12 h, indicating 
presence of unfolded proteins and increased need for correct protein folding. Also, several 
proteasomal subunits were up-regulated at mRNA level and one representative at protein 
level. Together with up-regulation of GRP94, VCP and sequestosome 1 (SQSTM1) this 
indicated induction of ERAD. Transcripts involved in the regulation of ER Ca2+ homeostasis 
like IP3R1 and IP3R3 were up-regulated. Further, measurement of Ca2+ levels indicated that 
DHA treatment for 12, 24 and 48 h increased the [Ca2+]i via Ca2+ release from the ER. DHA 
also enhanced the second phase of ATP-induced increase in [Ca2+]i, probably due to 
capacitative Ca2+ influx. These results imply that DHA treatment interferes with Ca2+ 
homeostasis in SW620 cells. Some pro-apoptotic transcripts like caspase 4 and caspase 7 
suggested a link between ER stress and induction of cell death. However, caspase 7 was not 
induced at protein level. The PERK target Nrf-2 and some of its downstream targets were up-
regulated at mRNA level, pointing towards a DHA-induced antioxidant response. The 
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cholesterol synthesis regulators HMG-CoAR, and the mature form of SREBP2 (mSREBP2) 
were induced at protein level upon DHA treatment. However, some transcripts encoding 
proteins involved in cholesterol biosynthesis were down-regulated and de novo cholesterol 
biosynthesis was found to decrease upon DHA treatment. Transcripts for some proteins 
involved in cholesterol uptake and transport like LDL receptor (LDLR) and niemann-pick 
disease type C1 (NPC1) were up-regulated, the latter also at protein level. This may reflect an 
increased need for cholesterol, but impaired ability to induce cholesterol synthesis. Total 
cholesterol level did not change at the earliest time points, but increased slightly after 48 h, 
while there was a reduction in synthesis of CEs from newly synthesized cholesterol. Taken 
together, these data imply that the growth inhibiting effect of DHA on the SW620 cells 
involves induction of ER stress, UPR and changes in Ca2+- and cholesterol homeostasis.  
 
Paper II 
The antiproliferative effect of EPA in HL-60 cells is mediated by alterations in calcium 
homeostasis 
Based on the results from paper I indicative of DHA-induced changes in Ca2+ homeostasis, 
the influence of such changes on n-3 PUFA sensitivity in cancer cells was further 
investigated. We used the human leukemia cancer cell lines HL-60 and E2R2 which represent 
an interesting cell model for studying the influence of changes in Ca2+ homeostasis on drug 
sensitivity and resistance, reflected by their different responses towards Ec and TG treatment. 
Incubation of HL-60 cells with EPA (35 μM) resulted in a strong growth inhibition, but had 
no effect on the growth of E2R2 cells. However, doubling the EPA concentration halved the 
growth of E2R2 cells while abolishing further proliferation of HL-60 cells, indicating a large 
difference between these two cell lines in the ability of handling the presence of EPA. Gene 
expression profiling was performed using the Affymetrix Human Genome U133 2.0 plus 
array. Gene expression results from EPA (35 μM) treatment of HL-60 cells after 12, 24 and 
48 h revealed changed expression of a high number of genes, representative for several 
different molecular pathways. Numbers of differentially expressed genes were highest after 
12 h (2974 up-regulated and 2247 down-regulated), decreased at 24 h (908 up-regulated and 
138 down-regulated) and was lowest after 48 h of EPA treatment (90 up-regulated and 11 
down-regulated). The transcription level of PERK and the ATF4 downstream targets ATF3 
and HMOX1 were up-regulated; indicating ER stress and activation of UPR. Induction of 
eIF2Į-P (3 h) and ATF4 (12 h), at protein level, revealed ER stress and UPR as early 
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responses during EPA treatment. Transcription and protein level of cyclin D1 was down-
regulated; suggestive of translational shutdown by eIF2Į-P. Transcription of several factors 
involved in protein folding like molecular chaperones such as Hsp90 and GRP94, and protein 
degradation like VCP, SQSTM1 (also at protein level) and proteasomal subunits were up-
regulated which points towards induction of ERAD. Transcription of Ca2+ homeostasis 
regulators like IP3R1 and CAMK1, and apoptosis like caspase 4 and caspase 7 were up-
regulated. Interestingly, in the E2R2 cells the protein levels of eIF2Į-P, ATF4, SQSTM1 and 
cyclin D1 remained unchanged upon EPA-treatment. These results suggest that the anti-tumor 
effect of EPA on HL-60 cells is mediated by changes in Ca2+ homeostasis and induction of 
ER stress and UPR.  
 
Paper III 
DHA alters expression of target proteins of cancer therapy in chemotherapy resistant 
SW620 colon cancer cells 
Gene expression results from paper I indicated changes in different cell signaling pathways 
upon DHA (70 μM)-treatment of SW620 cells for different time points. The work presented 
in this paper focused on changes in the expression of transcripts encoding important cell 
cycle- and apoptosis regulators; some of which are known chemotherapy targets. Changes in 
gene expression of cell cycle regulators acting at the G1/S checkpoint included up-regulation 
of p21 and down-regulation of CDK2, CDK4, cyclin D1, cyclin D3 and PCNA. Changes in 
expression of G2/M checkpoint regulators included up-regulation of stratifin and down-
regulation of CDK1, CDC25B, CDC25C, cyclin A2 and cyclin B2. Changes in expression of 
CDC25C, CDK1, p21 and stratifin were also confirmed at protein level. This indicates that 
both G1/S and G2/M checkpoints were affected by DHA. The ER stress-related pro-apoptotic 
transcripts GADD34, TRIB3, caspase 4 and caspase 7 were up-regulated, and CHOP 
increased at protein level, indicating sustained ER stress. Decreased total protein level of the 
cancer therapy target NFțB p65 and increased level of phosphorylated p38 MAPK also 
pointed towards induction of apoptosis. The malignancy-associated IAPs survivin (mRNA 
down-regulated) and livin (both Į- and ȕ isoforms) were reduced at protein level, while the 
apoptotic cleaved livin (tLivin) increased. These findings may add to the explanation of how 
DHA may enhance cancer chemotherapy treatments in vivo.  
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4. Discussion 
 
There is common concern about the reduced n-3 PUFA and increased n-6 PUFA intake, and 
hence increased n-6/n-3 ratio, in the Western diet today. This change in PUFA balance over 
the last century is reflected by a reduction of DHA in membrane phospholipids, which may 
lead to “life-style” diseases like cardiovascular disease and neurological disorders (reviewed 
in (38, 56)). The populations in Norway and Japan have a relatively high fish consumption 
level and they have a higher intake of n-3 PUFAs compared to USA which has a very low n-3 
PUFA intake, as outlined in the introduction (chapter 1.2, table 1). However, the n-3 PUFA 
intake is declining in Norway as well, as shown by the statistics department of FAO 
(FAOSTAT) in their food balance sheets for Norway; the fat supply quantity (g/capita/day) 
consumed from fish or seafood decreased from 6.6 g in 1977 to 4.9 g in 2007 (162). 
Colorectal cancer has been associated with the type of food we eat (reviewed in (163)), and 
this cancer form is very common in the Western world (164). Reduced n-6/n-3 ratio has been 
suggested to have a preventive effect on colorectal cancer (165) and be associated with 
reduced breast (166) and prostate (167) cancer risk. However, the results from studies 
reporting on n-6/n-3 ratio in relation to cancer are not consistent (reviewed in (168)). Reduced 
n-6/n-3 ratio also correlates with reduced death rate from cardiovascular disease (reviewed in 
(38)). A reduced n-6/n-3 ratio could be achieved by consuming more fatty fish or n-3 FO 
supplements, less plant oil containing n-6 PUFAs and use optimal cooking methods which 
preserves the n-3 PUFAs, as outlined in the introduction (chapter 1.2). 
Even though results from epidemiological observation studies reporting on fish, n-3 
PUFA intake and cancer are inconsistent, the meta-analysis of prospective cohort studies by 
Geelen et al revealed a 4 % and 3 % reduction in colorectal cancer risk per each extra fish 
meal or 100 g fish consumed per week, respectively (169). One of the studies included in this 
meta-analysis was the large European Prospective Investigation into Cancer and Nutrition 
Study, following over 470 000 people from 10 European countries. They found increased fish 
consumption to have a protective effect on colorectal cancer incidence (170). Few clinical 
studies on n-3 PUFAs and cancer have been performed, but the positive results from the 
intervention studies by Anti (60, 62), West (44), Aronson (61) and others, as outlined in the 
introduction (chapter 1.4.1), are convincing. However, the report from the FAO/WHO expert 
consultation in 2008 concluded that the evidence reporting on a possible relationship between 
n-3 PUFA consumption and cancer was insufficient at that time point (15). Even so, the report 
stated that there is a “probable” decrease in colorectal cancer risk correlated to intake of DHA 
46 
 
and EPA (500 mg/day) or ingestion of 2-3 portions of fish per week. The report also 
commented on some of the reasons why epidemiological observational studies have been 
unable to give concluding results on an effect of fat intake like n-3 PUFAs on cancers. 
Especially two factors were highlighted; the fact that fish also contains vitamin D and 
selenium which possibly have an effect against some cancers, and that food frequency 
questionnaires (FFQ) used to asses exposure levels may be error prone since they are not able 
to quantify the FAs accurately (15). This was also reflected in a report by Dennis et al where 
they reviewed the inconsistency in methods used to measure and report dietary fat and fatty 
acids in epidemiological studies of prostate cancer; differences in FFQs for dietary 
measurements, along with other factors, were reported to contribute to large heterogeneity 
between the reviewed studies (171). 
 
4.1 N-3 PUFAs changes the gene expression profiles of human cancer cells 
In the search for mechanisms involved in the anti-tumor effect of n-3 PUFAs, special 
attention has been given to lipid peroxidation and antioxidant defense, eicosanoid formation, 
changes in membrane characteristics and gene expression, as well as regulation of cell cycle 
and apoptosis (reviewed in (4, 10, 172)). Many studies have reported that n-3 PUFAs induce 
changes in expression of specific genes and proteins. However, the microarray technology 
brings the opportunity to study changes in gene expression in a new and genome wide 
manner. The technology is highly hypothesis-creating and exceptionally valuable in screening 
for drug-induced changes in gene expression and in nutritional transcriptomics, as mentioned 
in the introduction (chapter 1.6). Anyway, it is important to be aware of the fact that 
transcriptional changes cannot be directly related to changes at protein level. Gene expression 
can be regulated at different levels like mRNA synthesis, mRNA stability and regulation of 
translation; hence, biological interpretation of gene expression results requires further study 
like verification at protein level (reviewed in (173)). Some studies have presented microarray 
results from n-3 PUFA treated human cancer cells (97, 102, 115) and colon adenoma cells 
(174), all reporting changes in the expression of genes involved in regulation of cell growth. 
However, these studies have used microarrays covering only parts of the human genome. The 
gene expression profiling results presented in this thesis are based on two microarray types; 
one covering a selection of ~8500 well characterized human genes (paper I and III) and the 
second covering the whole human genome (paper II). Results indicated that n-3 PUFAs 
induced extensive changes in the expression of several genes belonging to several different 
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molecular pathways, in cancer cells (paper I, II and III). Some transcripts were highly up or 
down-regulated, whereas most differentially expressed transcripts showed moderate changes. 
However, the level of change in gene expression did not necessary correlate with the 
importance of specific transcripts when it comes to anti-tumor action of n-3 PUFAs. 
Differentially expressed genes were representative for e.g. induction of ER stress, UPR, 
changes in Ca2+- and cholesterol homeostasis, as well as changes in regulation of cell cycle 
and apoptosis (paper I, II and III). 
 
4.2 Induction of ER stress and UPR by n-3 PUFAs in human cancer cells 
The finding that n-3 PUFAs induced ER stress and UPR in human cancer cells is especially 
interesting and had to our knowledge not been shown before, at least not to the extent 
presented here. Even if all three branches of UPR were affected in DHA-treated SW620 cells, 
the n-3 PUFA-induced expression of PERK and targets downstream of ATF4 were striking in 
both SW620 (paper I, table 1) and HL-60 cells (paper II, table 2). Phosphorylation of eIF2Į 
(eIF2Į-P) is an important ER stress and UPR marker (reviewed in (126)), and was induced 
already 3 h after n-3 PUFA supplementation in both cell lines (paper I, fig. 2/3 and paper II, 
fig. 3). Together with induction of ATF4 (paper I, fig. 2/3 and paper II, fig. 3), this indicated 
that ER stress and UPR were early responses to n-3 PUFA treatment in these cancer cell lines. 
The reduction of eIF2Į-P over time in SW620 cells may be due to up-regulated GADD34 
(paper I, table 1), which dephosphorylates eIF2Į, as outlined in the introduction 
(chapter1.5.5). OA did not change eIF2Į-P or ATF4 protein levels; hence, it did not induce 
ER stress in SW620 cells (paper I, fig. 3). Previously, even if not referring to their 
observations as “ER stress” or “UPR”, Aktas et al found that EPA induced eIF2Į-P and 
expression of factors downstream of ATF4 in NIH3T3 cells (140). In line with our results, 
other FAs have also been found to induce ER stress in different cancer cells (175-178), 
indicating that not only n-3 PUFAs are capable of inducing ER stress.  
 Upon ER stress, eIF2Į-P leads to translational shutdown and reduction of cyclin D1 
which is an important G1 phase regulator (179, 180). Correlating with the induction of eIF2Į-
P, reduced cyclin D1 at both mRNA and protein level was observed after n-3 PUFA treatment 
in both SW620 (paper I, table 1, fig. 2/3) and HL-60 cells (paper II, table 2, fig. 3). Even 
OA reduced the cyclin D1 level slightly in SW620 cells, although to a much lesser extent and 
did not affect cell growth (paper I, fig. 3). Others have shown that OA did not affect the 
growth of HL-60 cells (181). Consistent with our results, Palakurthi et al showed that EPA 
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induced eIF2Į-P and reduced cyclin D1, leading to G1 cell cycle arrest in NIH3T3 cells. 
However, they ascribed eIF2Į-P to another eIF2Į kinase; protein kinase R (PKR) (113), while 
our results indicate that this happens through the PERK pathway in the cancer cells studied 
(paper I and II).  
 Protein folding in the ER requires an oxidative milieu and disturbances in the 
oxidative status of the ER may lead to ER stress and an increased production of ROS 
(reviewed in (126)). ROS may give oxidative damage on DNA and proteins as well as LPO 
and hence an increased need for antioxidants (reviewed in (182)). Gene expression profiling 
showed that DHA affected the antioxidant response of SW620 cells, as indicated by up-
regulated expression of Nrf-2 and its target HMOX1 (paper I, table 1) which was one of the 
highest up-regulated transcripts. However, short interference RNA (siRNA) knockout of 
HMOX1 did not affect cell growth during DHA-treatment (paper I, results not shown). Nrf-2 
may be activated by PERK in a ROS- and eIF2Į-P independent manner (183) and has an 
important role in the redox balance in cells. Nrf-2 induces glutamate-cysteine ligase (GCL) 
which is the rate limiting enzyme in biosynthesis of the cellular redox buffer glutathione 
(reviewed in (182)); hence, up-regulated GCL catalytic (GCLC) and modifier (GCLM) 
subunits point towards an up-leveling of the antioxidant defense in DHA-treated SW620 cells 
(paper I, table 1). Further, we recently found DHA-induced increase in ROS production at 
early time points (1-4 h), correlating with induction and nuclear translocation of Nrf-2 in 
SW620 cells (Overland et al, submitted). However, the antioxidant vitamin E did not relieve 
DHA-induced growth inhibition (104); hence, LPO is probably not the main cause of the anti-
tumor effect of DHA in the SW620 cells. EPA-treatment of HL-60 cells was previously 
shown to induce ROS production; hence oxidative stress was suggested to be involved in 
triggering cell death in these cells (152). However, Finstad et al showed that vitamin E did not 
reduce the effect of EPA on HL-60 cells (184).  
Upon accumulation of misfolded proteins in the ER, the ERAD process is activated 
(reviewed in (121)). The up-regulated expression of several n-3 PUFA-induced proteasomal 
subunits and Hsps/chaperones in cancer cells (paper I, table 1, supplementary table 1 and 
paper II, table 2), like induction of 26S proteasome regulatory subunit RPN2 
(RPN2/PSMD1) and Hsp70 in DHA-treated SW620 cells (paper I, table 1, fig. 2), may 
indicate presence of unfolded proteins in the ER lumen and that cells are signaling an 
increased need for ERAD components. This is also reflected by the up-regulated expression 
of GRP94/HSP90B1, which may be considered a hallmark of ER stress responses, in both 
SW620 (paper I, supplementary table 1) and HL-60 cells (paper II, table 2). It has several 
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functions during ER stress such as chaperone-induced protein folding, Ca2+-binding and 
targeting of proteins for ERAD (reviewed in (185)). This ubiquitin selective chaperone VCP 
and SQSMT1 are also important in ERAD. VCP disassembles protein complexes and 
translocates proteins from ER to the proteasomes in cytosol, but is also important in cell cycle 
regulation (reviewed in (186)). SQSTM1 is induced upon accumulation of unfolded proteins 
(reviewed in (187)); hence, the up-regulated expression of these ERAD components by n-3 
PUFA treatment in both of the profiled cancer cell lines (paper I, table 1 and paper II, table 
2, fig. 3) strengthens the suggestion of ERAD induction.  
Increased expression of ER stress-induced pro-apoptotic transcripts points towards 
sustained ER stress. The induction of CHOP during DHA-induced ER stress in SW620 cells 
(paper III, fig. 2) is especially interesting and consistent with previous studies (140, 188). 
CHOP may be induced by all three UPR branches and regulates the balance between pro- and 
anti-apoptotic BCl-2 family proteins (as outlined in chapter1.5.5), thereby affecting the 
balance between protective UPR and induction of cell death (reviewed in (121)). The BID 
transcript was up-regulated in DHA-treated SW620 cells (paper I, supplementary table 1) and 
others have found activation of BID to be involved in EPA-induced apoptosis of HL-60 cells 
(152). Also, the BCl-2/adenovirus E1B 19 kDa interacting protein 3-like (BNIP3L) transcript 
was up-regulated by n-3 PUFA treatment in both SW620 and HL-60 cells (paper I, re-
examination of gene list and paper II, table 2). BNIP3L may interact with BCL-2 (189), and 
BNIP3L overexpression reduced the growth of SW480 colon cancer cells (190). Taken 
together, this may illustrate why we find ER stress to be induced early after n-3 PUFA 
exposure, while changes in cell growth and DNA synthesis appear later. Recently, we used 
the xCELLigence RTCA DP instrument (Roche) to monitor cell growth in real time during 
DHA treatment of SW620 cells. Cell index declined after 10-15 h of DHA (but not OA) 
treatment in these cells (Overland et al, submitted).  
Sustained ER stress is also indicated by up-regulated XBP-1 (paper I, table 1) and its 
target C/EBPȕ (191) in both n-3 PUFA-treated SW620 and HL-60 cells (paper I and II, re-
examination of gene lists). The C/EBPȕ LIP isomer has been found to increase during 
prolonged ER stress, attenuate ATF4-dependent transcription and probably be pro-apoptotic 
(192). Recently, we also found LIP and the LIP/liver activator protein (LAP) ratio to be 
increased upon tetradecylthioacetic acid (TTA)-treatment of SW620 cells (193). Increased 
LIP has been found important for CHOP-induced apoptosis (194), and C/EBPȕ/CHOP may 
be important for the up-regulation of TRIB3 (195). TRIB3 was up-regulated by n-3 PUFA 
treatment in both cell lines tested (paper I, table 1 and paper II, table 2) and may promote 
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apoptosis through inhibiting AKT (196) and NFțB (197). In addition, up-regulated GADD34 
(paper I, table 1) and caspases 4 and 7 (paper I, table 1 and paper II, table 2, reviewed in 
(198)), as well as calpains (paper I, table 1, (199)) have been implicated in ER stress-induced 
apoptosis. However, we were not able to detect activated caspase 7 (paper I, results not 
shown) or observe apoptosis in DHA-treated SW620 cells (104), while others have found 
EPA-induced apoptosis in HL-60 cells, as discussed below (chapter 4.5).    
Extensive ER stress may also induce the expression of genes involved in autophagy 
(reviewed in (122)). Further examination of differentially expressed genes (paper I and II) 
revealed that the already mentioned up-regulated transcripts: SQSTM1/p62, VCP (200), 
BNIP3L (201) and C/EBPȕ (202), in addition to LC3B (reviewed in (187), re-examination of 
gene lists paper I) were also implicated in autophagy. This may indicate induction of 
autophagy upon n-3 PUFA treatment of SW620 and HL-60 cells. Also, we recently showed 
that DHA treatment up-regulated several important UPR and autophagy factors as early as 
after 3 and 6 h in SW620 cells, however, this did not result in increased autophagy level in 
these cells (Overland et al, submitted). Even so, Jing et al newly found that DHA induced 
autophagy and apoptosis in cervical cancer that was p53 dependent (203). 
 ER stress and UPR are known to play a role in some human diseases. Even if 
induction of UPR correlates with survival of some tumors, as discussed in chapter 1.5.5, UPR 
may be detrimental in other diseases like retinitis pigmentosa in which misfolded mutant 
rhodopsin protein leads to apoptosis, degeneration of the retina and hence results in blindness 
(reviewed in (204)). ER stress and UPR are also implicated in the pathogenesis of obesity and 
transcriptional regulation of lipogenesis through all three arms of UPR (reviewed in (205, 
206)). Our results show that DHA- and EPA-induced ER stress and UPR in human cancer 
cells correlated with reduction of cell growth (paper I and II). However, in search for 
relevant biomarkers for prediction of PUFA-sensitivity or targeted therapies, there is a need 
for more research on the molecular mechanisms involved. Currently, different UPR-based 
“anti-tumor” drugs are being explored and tested, both in the laboratory and the clinic. Given 
the fact that UPR can be both protective and death-inducing, such drugs may be directed at 
changing the balance of UPR towards induction of cell death. This can be achieved e.g. by 
inhibiting proteasomal degradation and thereby ERAD; resulting in extensive ER stress and 
apoptosis (reviewed in (207)).  
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4.3 N-3 PUFAs disturb Ca2+ homeostasis in human cancer cells 
Proper regulation of the Ca2+ homeostasis in the ER is important in maintaining overall ER 
homeostasis (reviewed in (121)). Gene expression results indicated that DHA interfered with 
the expression of some genes like IP3Rs involved in regulation of Ca2+ homeostasis in the 
SW620 cells (paper I, table 1, supplemental table 1). Measurement of  cellular Ca2+ levels 
showed that DHA increased the [Ca2+]i, probably by triggering Ca2+ release from the IP3 
sensitive ER Ca2+ store and increasing capacitative Ca2+ flux into cells (paper I, fig. 4). 
Consistent with our results, Aires et al previously found that DHA increased [Ca2+]i via IP3-
dependent release from intracellular Ca2+ stores and capacitative Ca2+ entry in leukemia cells 
(143). Chow et al also demonstrated an n-3 PUFA-induced two phasic increase in [Ca2+]i in a 
leukemic cell line, however, the increase in [Ca2+]i mobilized from the ER Ca2+ pool did not 
depend on IP3 and the second phase lower Ca2+ level was not due to Ca2+ influx (208). Some 
studies have found that DHA and/or EPA reduced the TG-induced rise in [Ca2+]i by inhibiting 
TG-induced capacitative Ca2+ influx (113, 148). This is contradictory to our observation in 
DHA-treated SW620 cells where we found DHA supplementation to increase [Ca2+]i to an 
even higher level than TG alone (paper I, fig. 4). Hence, results on the capability of n-3 
PUFAs to affect capacitative influx are not consistent for unknown reasons. Interestingly, 
capacitative Ca2+ influx is currently believed to include STIM and ORAI proteins (reviewed 
in (142)). Reentry of the gene expression results (paper I) showed that STIM1 was up-
regulated at 24 and 48 h upon DHA-stimulation in SW620 cells. This may be to increase 
capacitative Ca2+ flux into cells, in order to refill the ER Ca2+ store. The up-regulated calcium 
modulating ligand (CAMLG) (paper I, table 1) is also worth mentioning, since it is known to 
induce Ca2+ flux in to cells (209). OA has been shown to inhibit TG-induced capacitative Ca2+ 
influx (149, 210). OA was not included in the Ca2+ measurements, however, we may speculate 
that the influence of OA on Ca2+ transport is different from DHA, and hence OA did not 
induce ER stress in the SW620 cells (paper I).  
It is possible that the observed disturbance in Ca2+ homeostasis is linked to induction 
of ER stress in SW620 cells. The measurements of the effect of DHA on Ca2+ levels in 
SW620 cells were performed at late time points. Considering the early induction of eIF2Į-P 
(3 h) and ATF4 (6 h) the observed changes in Ca2+ homeostasis could be a result of, rather 
than the cause of, ER stress induction. These experiments should be repeated at earlier 
treatment time points in order to explore whether there could be an initial transient Ca2+-
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release prior to the observed ER stress or not. Some previous studies have reported that n-3 
PUFAs induces a rapid increase in [Ca2+]i in some cancer cells (113, 143, 208).  
 The findings of ER stress and UPR induction, as well as changes in the [Ca2+]i led us 
to suggest that regulation of Ca2+ homeostasis may be important in the “anti-tumor” effect of 
n-3 PUFAs. In order to further investigate this hypothesis, we took advantage of the already 
described HL-60/E2R2 cancer cell model in which the two cell lines respond differentially to 
the Ca2+ homeostasis disturbing chemicals Ec and TG (150). Zhang et al showed that in 
contrast to HL-60 cells, E2R2 cells displayed sustained protein synthesis levels and did not 
induce eIF2Į-P upon Ec/TG treatment, which may reflect decreased stress in the E2R2 cells 
possibly due to increased capacitative influx and increased refilling of the ER (150). We 
hypothesized that these two cell lines would respond differentially to n-3 PUFA 
supplementation. EPA (35 μM) did indeed induce strong growth inhibition of HL-60 cells, 
while E2R2 cells were resistant (paper II, fig. 2). These results correlated with an early 
induction of eIF2Į-P (3 h) and ATF4 and reduction of cyclin D1 only in HL-60 cells (paper 
II, fig. 3). Hence, induction of ER stress and UPR, and translational shutdown was not 
observed in the E2R2 cells. Based on this we suggested that the degree of n-3 PUFA 
sensitivity correlated with the differences in regulation of Ca2+ homeostasis between these cell 
lines. It has been shown that PUFAs and Ec may mobilize Ca2+ from the same intracellular 
Ca2+ store (211). We did not measure Ca2+ release in this cancer cell model. However, the 
gene expression profiling of HL-60 cells showed up-regulation of several genes involved in 
regulation of Ca2+ homeostasis like IP3R, which may indicate increased need of such 
receptors to regulate Ca2+ release from the IP3-sensitive ER Ca2+ store (paper II, table 2). It 
would be interesting to explore and compare the effect of n-3 PUFAs on [Ca2+]i in this model.  
Recently it was reported that Ec resistance in the E2R2 cells correlated with high 
overexpression of the ATP-binding cassette, sub-family F (GCN20), member 1 
(ABC50/ABCF1) gene which has a role in translation initiation. Overexpression of ABC50 in 
HL-60 cells decreased sensitivity towards Ec, decreased eIF2Į-P, increased ribosomal content 
and increased protein translation, while ABC50 knockdown in E2R2 cells gave the opposite 
characteristics; hence increased the Ec sensitivity in these cells (212). Reinspection of gene 
expression results (paper II) revealed that ABC50 was down-regulated upon EPA treatment 
in HL-60 cells. This may be consistent with EPA-induced growth inhibition, induction of 
eIF2Į-P and translational shut down in HL-60 cells, but not in E2R2 cells (paper II). If the 
expression of ABC50 is affected by EPA in the E2R2 cells remains to be investigated.   
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In light of our results it is tempting to speculate that the differences in sensitivity to n-3 
PUFAs are correlated with differences in capability of cancer cells to handle changes in Ca2+ 
homeostasis. This may be reflected by a study by Palakurthi et al reporting that the cancer cell 
line U118-MG had a low half maximal inhibitory concentration (IC50) value of 36 μM EPA 
and induced a rapid increase in Ca2+ level, while the less sensitive cancer cell line HTB-174 
had a high IC50 value of 80 μM and did not give such a rapid increase in Ca2+ level. Hence, 
the degree of EPA sensitivity correlated with the ability to increase in [Ca2+]i in these cancer 
cells (113). 
 
4.4 DHA deregulates lipid metabolism in cancer cells  
The ER homeostasis is sensitive to changes in cholesterol homeostasis (reviewed in (121)). 
Interestingly, we found induction of the important cholesterol synthesis regulators SREBP2 
(mature form) and HMG-CoAR in DHA-treated SW620 cells (paper I, fig. 5), in addition to 
up-regulated expression level of some genes encoding proteins involved in cholesterol 
synthesis, uptake and transport like LDLR and NPC1 (paper I, table 1, supplementary table 
1, fig.5). This could indicate an increased need for cholesterol synthesis upon DHA 
supplementation. Based on these results, we measured de novo cholesterol synthesis which 
turned out to be down-regulated (paper I, fig. 6), accompanied by some down-regulated 
cholesterol synthesis transcripts (paper I, table 1). However, the total cholesterol level in 
these cells did not change markedly (paper I, results not shown). Taken together with the 
previous observations of accumulated DHA-rich CEs and accumulation of lipids in lipid 
droplets upon DHA treatment of SW620 cells (104), these results suggested a redistribution of 
cholesterol from the free form into CEs. The reduction in de novo cholesterol synthesis and 
the accumulation of CEs could possibly lead to depletion of free cholesterol in the ER. DHA 
supplementation of CaCo-2 cells has been shown to reduce cholesterol transport from the 
plasma membrane to the ER (213). A similar event in SW620 cells may contribute to reduced 
ER cholesterol level. Cholesterol depletion may induce ER stress and UPR (214), which could 
be responsible for the activation of SREBP2 (138). Consistent with the observed reduction in 
cholesterol synthesis, previous studies have reported that n-3 PUFAs reduced HMG-CoAR 
mRNA level (101, 102, 215) and nuclear SREBP2 (105), as well as induced LDLR in cancer 
cells (215, 216). Hence to our knowledge, we are the first to report activation of SREBP-2 
upon n-3 PUFA supplementation of cancer cells.   
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A possible explanation for reduced cholesterol synthesis and reduced expression of 
some cholesterol synthesis genes could be that ER stress-induced ATF6 might interfere with 
SREBP2-regulated gene expression by binding the active transcription factor and thereby 
reducing its activity (139). However, we recently showed that down-regulated expression of 
some SREBP2 target genes (as early as after 6 h) and increased activated SREBP2 level were 
most likely regulated independently of ER stress and ATF6 during DHA-treatment of SW620 
cells. This was also reflected by the induction of SREBP2 by OA (217), which did not induce 
ER stress (paper I, fig. 3) or accumulation of CEs (104) in these cells. The observed 
deregulation of cholesterol synthesis by DHA supplementation needs to be further examined.  
In addition to SREBP2, cholesterol synthesis is also known to be induced by 
SREBP1a (reviewed in (42)). Consistent with our previous finding of reduced nuclear 
SREBP1 protein upon DHA-treatment of SW620 and SW480 cells (104), we found SREBP1 
expression to be down-regulated (paper I, supplementary table 1). Others have also found 
reduced SREBP1 mRNA and protein level upon n-3 PUFA supplementation (103, 105). 
SREBP1 also regulates lipogenesis e.g. through induction of FAS, and consistent with the 
results of others (101), the expression of FAS was also reduced by DHA-treatment of SW620 
cells (paper I, reinspection of gene lists). Whether the reduction of SREBP1 may cause 
down-regulation of the expression of some cholesterol biosynthesis genes upon DHA-
treatment needs to be further investigated. Interestingly, SREBP nuclear levels were recently 
shown to be influenced by the mTORC1 pathway; inhibition of mTORC1 resulted in 
increased nuclear localization of lipin 1 which could reduce nuclear SREBP (218). 
Reinspection of the gene lists (paper I) revealed that Akt1 expression was down-regulated 
which may lead to reduced mTORC1 activation. The expression of lipin 1 was up-regulated in 
DHA-treated SW620 cells (complementary unpublished results). 
The finding of reduced incorporation of newly synthesized cholesterol into CEs 
(paper I, fig. 6) correlates with the previous observation of reduced ACAT1 mRNA and 
protein level upon DHA-treatment of SW620 cells. However, reduction of ACAT1 took place 
after 24 h and beyond (104); hence there is time for accumulation of CEs preceding this 
reduction and ACAT1 reduction could possibly be a feedback mechanism to this 
accumulation. Further, accumulation of DHA-rich CEs in lipid droplets could possibly be due 
to reduced CE turnover. This speculation is supported by the finding of down-regulated gene 
expression of neutral cholesterol ester hydrolase 1 (NCEH1, complementary unpublished 
results) in DHA-treated SW620 cells. NCEH1 degrades CEs from cytosolic lipid droplets 
(reviewed in (219)); hence its reduction could lead to accumulation of CEs in lipid droplets. 
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Interestingly, knockdown of NCEH1/KIAA1363 has been found to reduce growth of cancer 
cell xenografts in vivo (220).  
Cholesterol depletion has been reported to induce autophagy (221, 222) and induce 
SREBP2-dependent transcription of several autophagy genes like LC3B, possibly in order to 
induce autophagy of lipid droplets to access the sterols stored therein (221). This could be 
consistent with our observations of activated SREBP2, a possible local cholesterol depletion 
in the ER (paper I) and induction of the expression of autophagic genes after DHA treatment 
of SW620 cells, even though it did not correlate with increased autophagy in these cells 
(Overland et al, submitted). This is also reflected by the accumulation of cytosolic lipid 
droplets (104) whose degradation has been shown to be regulated by autophagy-dependent 
lipolysis (macrolipophagy) (223). Interestingly, Velikkakath et al recently showed that the 
autophagy protein Atg2 co-localized with lipid droplets and found that knockout of Atg2A 
and Atg2B resulted in accumulation and clustering of lipid droplets in HeLa cells (224). The 
relation between cholesterol, lipid droplets and autophagy was lately reviewed in (225). 
 As an important component of cellular membranes, cholesterol is essential for cell 
growth (reviewed in (41)) and cancer cells may have a higher demand for cholesterol in order 
to keep up membrane synthesis in rapidly growing cells (226). Cholesterol starvation has been 
shown to decrease CDK1 activity and arrest cancer cells in the G2 phase of the cell cycle 
(227). This is also reflected in a study by Kaneko et al who showed that the HMG-CoAR 
inhibitor lovastatin down-regulated the IAP survivin that is normally active in the G2/M 
phase. They also found that siRNA against survivin induced apoptosis in SW480 cells (228). 
Hence, there seems to be a link between the reduction in cholesterol biosynthesis (paper I) 
and the previously observed G2/M arrest (104) via reduction of CDK1 and survivin (paper 
III, table 1, fig. 2) after DHA-supplementation of SW620 cells. However, we recently showed 
that cholesterol supplementation in combination with DHA did not effect DHA-induced 
growth inhibition of these cells (217).  
 
4.5 N-3 PUFAs affect G1/S and G2/M cell cycle checkpoints and regulation 
of apoptosis
Based on previous reports of cell cycle arrest in the G2/M and G1 phases of DHA-treated 
SW620 cells (104) and EPA-treated HL-60 cells (184), respectively, the changed expression 
of cell cycle regulators was expected (paper II, table 2 and paper III, table 1, fig. 1). Others 
have also reported n-3 PUFAs to arrest cancer cells in the G1 and G2/M cell cycle phases (88, 
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108-112). However, in DHA-treated SW620 cells both G1 and G2/M phase regulators were 
differentially expressed; hence DHA probably affected both of these phases simultaneously. 
Down-regulated transcription of G1 phase cyclin D and CDKs in DHA-treated SW620 cells 
(paper III, table 1, fig. 2) may indicate a hinder from passing on to the G2/M phase. DHA-
induced p21 (paper III, table 1, fig. 2) may inhibit cyclin-CDK complexes at both the G1/S 
and G2/M checkpoints (reviewed in (229)) and down-regulate PCNA (paper III, table 1), in 
order to halt cell cycle progression (reviewed in (230)). Consistently, others have also 
reported n-3 PUFAs to induce changes in the expression of p21 (97, 112), CDK2 (88, 112), 
Cyclin A (88, 112) and PCNA (114). Re-examination of the gene lists from paper II revealed 
up-regulated expression of the G1 cell cycle inhibitors p18 and p27, as well as down-
regulated expression of CDK4 and cyclins D1-3 and cyclin E in EPA-treated HL-60 cells 
(paper II, table 2); hence indicating G1 arrest. Changed transcription of p18 and p27 were 
previously reported in DHA-treated colon cancer cells (115). 
 The G2/M phase was also clearly affected by DHA treatment of SW620 cells, as 
shown by down-regulated expression for several different G2/M phase regulators (paper III, 
table 1). The reduction of nuclear CDK1 and CDC25C (paper III, fig. 2) may be due to 
increased cytosolic SFN (paper III, fig. 2) which binds and retains these proteins in the 
cytoplasm (reviewed in (231)). This, in addition to down-regulation of G2/M cyclins (paper 
III, table 1), may be critical for induction of G2/M arrest in SW620 cells. To our knowledge, 
DHA-induced SFN, as well as reduced CDK1 and CDC25C have not been reported 
previously.   
 In a review on PUFAs and induction of apoptosis in cancer cells, Serini et al (75) 
commented on our results from paper I. Given the fact that conjungated-LA (CLA) has been 
reported to induce ER stress-associated apoptosis in breast cancer cells (175), they suggested 
looking for apoptosis following PUFA-induced ER stress in colon cancer cells. However, 
even if DHA induced changes in different biological pathways that may lead to apoptosis 
(paper I and III), we have not able to show induction of apoptosis in SW620 cells by 
TUNEL-assay (104) or activation of caspase 7 (paper I, results not shown). Consistent with 
our results, Chen et al could neither demonstrate apoptosis in SW620 cells upon DHA-
treatment, even if DHA induced apoptosis and detectable DNA ladder in SW480 cells in the 
same study (85). It is important to note that Chen et al used double the DHA concentration 
(150 μM) compared to paper I and III (70 μM). However, both concentrations are 
physiologically relevant (22). Intriguingly, Huerta et al found that SW620 cells were more 
resistant to apoptosis than SW480 cells, and that SW620 cells expressed less of some 
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important apoptotic factors, while the survivin level was higher in SW620 cells compared to 
SW480 cells, and only SW620 cells expressed the NFțB p65 (232). Considering that the fact 
that SW480 and SW620 cell lines origin from a primary tumor and a lymph node metastasis 
of a human Duke’s stage B colon adenocarcinoma, respectively, and most likely have a 
monoclonal origin (233), this may indicate that the ability to induce apoptosis is reduced 
during progression from primary tumor to metastasis (232). Consistent with the growth 
inhibiting effect of n-3 PUFAs on the SW620 cells in vitro (104), we also showed this effect 
in vivo by feeding nude mice a diet containing FO compared to CO in the control diet. Three 
weeks after initiation of SW620 xenografts, tumor growth was reduced, the n-3 PUFA level 
increased, while the n-6 PUFA level decreased. The FO diet also reduced the phosphocholine 
level in these cells (70) which is known to be increased in different cancers (reviewed in 
(234)).  
 Several pro-apoptotic transcripts were up-regulated after 12 h of EPA supplementation 
in HL-60 cells, including five different caspases like the ER stress-implicated caspases 4 and 
7 (paper II, table 2). Consistent with these results, Arita et al found that EPA reduced HL-60 
cell growth in a time- and dose dependent manner, induced apoptosis (above 60 μM for more 
than 6 h), induced cytochrome C, increased mitochondrial membrane potential and cleaved 
BID (152). Other studies have also shown that DHA and/or EPA may induce growth 
reduction and/or apoptosis/necrosis in HL-60 cells (181, 184, 235-237) and other human 
cancer cells (reviewed in (75)). 
 
4.6 Known anti-tumor targets affected by DHA 
PUFAs are emerging as a nontoxic supplement to cancer therapy. It seems to be well tolerated 
by humans and do not give harmful side effects during clinical trials (61, 64, 68). In cell 
culture and animal experiments, n-3 PUFAs in combination with conventional cancer therapy 
have shown increased effect of chemotherapeutic drugs such as doxorubicin and radiation of 
different cancer types, as well as reduction of chemotherapeutic side effects (reviewed in 
(74)). Gene expression profiling of DHA-treated SW620 cells revealed changes in expression 
of genes which are known targets for cancer therapy. Reduction of the IAPs survivin and livin 
(both Į- and ȕ isoforms), and induction of the apoptotic cleaved livin (tLlivin) at protein level 
were especially interesting (paper III, fig. 2). Survivin and livin have been associated with 
cancer malignancy and found to be up-regulated in different cancers (reviewed in (238)) like 
colorectal cancer in which their expression was inversely correlated with overall survival 
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(239). Interestingly, Calviello et al previously showed that DHA supplementation to SW480 
cells reduced survivin in a time- and dose dependent manner (120). Also, knockdown of 
survivin mRNA by siRNA increased the sensitivity of radiation-induced apoptosis and 
arrested SW480 cells in the G2/M phase (240). 
Since NFțB is constitutionally active in several cancers and facilitates tumorigenesis, 
the NFțB-pathway is very interesting for therapeutic targeting in cancer. Unfortunately, 
several chemotherapies are known to activate NFțB, which may lead to resistance towards 
the apoptosis inducing effect of these agents (reviewed in (71)). Therefore we were exited to 
find that DHA-treatment of SW620 cells decreased NFțB p65 (Rel A) at both mRNA and 
protein level (paper III, table 1, fig. 2). Others have also found n-3 PUFAs to interfere with 
the expression and activity of NFțB (reviewed in (71)). Consistent with our results, 
Narayayan et al found that DHA reduced both NFțB p65 and cyclin D1 at protein level in 
colon cancer cells (89). Interestingly, ER stress may activate NFțB at an early stage through 
all three UPR branches and increased [Ca2+]i or ROS, but also inhibit NFțB if the stress is 
persistent through e.g. C/EBPȕ (reviewed in (241)). In addition, NFțB can be activated by 
AKT (reviewed in (71)), but this may be counteracted and lead to induction of apoptosis 
through TRIB3 inhibition of AKT (196). NFțB may also inhibit CHOP (242) and interfere 
with the regulation of the ER Ca2+ storage (243).  Hence the DHA-induced reduction of NFțB 
p65 in cancer cells is an important finding. 
The DHA-induced up-regulation, phosphorylation and hence activation of p38 MAPK 
was also an interesting finding (paper III, table 1, fig. 2). In addition to its well-known role in 
proliferation inhibition (reviewed in (244)), p38 MAPK is also known to be activated during 
ER stress, and may increase the activity of CHOP (reviewed in (198)). Activation of p38 
MAPK has also been suggested as a link between induction of ER stress and ER stress-
induced apoptosis and autophagy (245). Further, the anticancer drug celecobix may activate 
p38 MAPK which is implicated in the down-regulation of survivin and induction of growth 
inhibition and apoptosis in colorectal cancer cells (246). Others have also found activated p38 
MAPK to be involved in the anti-tumor effect of n-3 PUFAs (106, 247). However, the role of 
p38 MAPK in growth regulation is not clear; some studies have reported a pro-survival role of 
p38 MAPK in cancer cells and assign it a role in metastasis. Therefore caution should be 
taken when manipulating p38 MAPK for therapeutic purposes (reviewed in (244)).  
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4.7 Different cancer cells may respond differently to n-3 PUFA treatment  
Animal and cell culture experiments have shown that n-3 PUFAs may have anti-tumor 
effects. However, the degree of n-3 PUFA sensitivity may vary substantially between 
different cell lines. Both SW620 and HL-60 cells are sensitive towards quite low doses of 
DHA and EPA (104, 184), as are several other cancer cell lines from various tissues, while 
some cancer cell lines seem to be very resistant towards these n-3 PUFAs (113, 184, 248). 
Ding et al showed that the IC50 values of DHA treatment of different cancer cell lines varied 
between ~5-300 μM for the most sensitive and the most resistant, respectively (248). The 
wide spectra in n-3 PUFA sensitivity between different cancer cells was also reflected by the 
study of Palakurthi et al who tested the growth reduction potential of EPA in several different 
human cancer cell lines (113). Several factors, probably both known and unknown may be 
considered in this context since different types of cells display different characteristics; they 
have different gene- and protein expression which is likely to be very important for their 
response to different types of stimuli. Therefore different cancer cell lines may respond to 
exposure of n-3 PUFAs through several different pathways and the degree of growth 
inhibition or cell death may vary substantially. In addition, Diggle reviewed several factors 
that may influence the outcome of in vitro studies reporting on the association between 
PUFAs and cancer; cell type differences, grade and stage of tumors, differences in cell 
cultivation conditions (cell density and medium contents), specific PUFA characteristics 
(number of double bonds and chain length), as well as PUFA concentration and exposure time 
(249). Hence, some of these factors may possibly explain why our results show that DHA (35 
and 70 μM), but not OA (70 μM), induced ER stress at in the SW620 colon cancer cells 
(paper I, fig. 3), while Caviglia et al reported that 400-1200 μM OA, but not 200-800 μM 
DHA, induced ER stress in a hepatoma cell line (176). It is tempting to mention that 
supplementation of SW620 cells with 105 μM almost completely abolished further growth, as 
assessed by MTT assay (unpublished complementary results). In addition, how n-3 PUFAs 
are delivered to cancer cells; as LDL, bound to albumin (250) or FFAs (paper I, II and III), 
may also be of importance.  
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5. Conclusion and future perspectives 
Extensive research has been performed on the possible anti-tumor effect of n-3 PUFAs. 
However, in order to use these PUFAs in cancer prevention or as a supplement to already 
established cancer therapies it is important to elucidate the molecular mechanisms behind this 
effect. By taking advantage of the microarray technology, we found that n-3 PUFAs induced 
extensive changes in the gene expression profiles of cancer cells. Early responses were ER 
stress and induction of the UPR, which correlated with changes in Ca2+ and cholesterol 
homeostasis. These changes may lead to cell cycle arrest and possibly induction of autophagy 
and cancer cell death. Importantly, DHA supplementation had a favorable effect on known 
cell cycle regulators and cancer therapy targets. These results may contribute to the 
understanding of how natural n-3 PUFAs exert their anti-tumor effect on cancer cells and how 
they may enhance the effect of conventional cancer chemotherapies. 
The observed n-3 PUFA-induced ER stress, UPR and changes in Ca2+ and cholesterol 
homeostasis should be further studied in the established and other cancer cell models, as well 
as normal cells, to explore if these responses are cancer cell specific and common between 
different cancer cell types. If cancer cell specific, the differences between normal and 
cancerous cells counting for these differences should be studied. Further studies are also 
needed to explore the effect of n-3 PUFAs on cancer therapy target genes and proteins. Also, 
the presented microarray studies have potential for further investigation of different 
mechanisms involved in the anti-tumor effect of n-3 PUFAs on cancer cells. In addition, it 
would be interesting to study the relation between lipids and autophagy (lipophagy) upon n-3 
PUFA treatment, as well as the n-3 PUFA effect on micro RNAs in cancer cells.  
In the context of personalized diagnostics and treatment, it is likely that specific 
transcriptomic or proteomic profiles could help reveal patients who would benefit more or 
less from co-treatment with chemotherapy and specific n-3 PUFAs. This could help reveal 
possible biomarkers related to n-3 PUFA sensitivity in cancer cells. Whether n-3 PUFAs have 
potential as supplements to clinical cancer treatment needs to be further elucidated. Especially 
clinical studies are needed, focusing on cancer prevention and cancer therapy co-treatment, as 
well as the understanding of the molecular mechanisms involved. Such studies should strictly 
control preparation and intake of n-3 PUFA dietary sources.  
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Abstract Polyunsaturated fatty acids (PUFAs) are normal
constituents of the diet, but have properties different from
other fatty acids (e.g., through generation of signaling mole-
cules). N-3 PUFAs reduce cancer cell growth, but no unified
mechanism has been identified. We show that docosahexae-
noic acid (DHA; 22:6 n-3) causes extensive changes in gene
expression patterns at mRNA level in the colon cancer cell
line SW620. Early changes include unfolded protein re-
sponse (UPR) and increased levels of phosphorylated eIF2a
as verified at protein level. The latter is considered a hall-
mark of endoplasmic reticulum (ER) stress and is abun-
dantly present already after 3 h. It may coordinate many
of the downstream changes observed, including signaling
pathways for cell cycle arrest/apoptosis, calcium homeosta-
sis, cholesterol metabolism, ubiquitination, and proteasomal
degradation. Also, eicosapentaenoic acid (EPA), but not
oleic acid (OA), induced key mediators of ER stress and
UPR at protein level. Accumulation of esterified cholesterol
was not compensated for by increased total levels of choles-
terol, and mRNAs for cholesterol biosynthesis as well as de
novo synthesis of cholesterol were reduced. These results
suggest that cytotoxic effects of DHA are associated with sig-
naling pathways involving lipid metabolism and ER stress.—
Jakobsen, C. H., G. L. Størvold, H. Bremseth, T. Follestad, K.
Sand, M. Mack, K. S. Olsen, A. G. Lundemo, J. G. Iversen,
H. E. Krokan, and S. A. Schønberg. DHA induces ER stress
and growth arrest in human colon cancer cells: associations
with cholesterol and calcium homeostasis. J. Lipid Res. 2008.
49: 2089–2100.
Supplementary key words gene expression • phosphorylated eIF2a •
antioxidant response • heat shock response • cytosolic free Ca21 • cell
cycle • total cholesterol level • cholesterol synthesis
Long-chain polyunsaturated fatty acids (PUFAs) of the
n-3 type are important dietary components that may pre-
vent or alleviate coronary heart disease and inflammatory
conditions (1, 2). Even though epidemiological studies on
the association between fish consumption and cancer risk
are not consistent, evidence from animal- and cell-culture
studies demonstrate that PUFAs inhibit cancer-cell growth,
induce apoptosis, and increase the efficiency of chemo-
therapeutic drugs (3–5). Several mechanisms have been
proposed for the antiproliferative effect of n-3 PUFAs;
among these are alterations in eicosanoid formation (6),
lipid peroxidation initiated by free radicals (7–9), accumu-
lation of cytotoxic lipid droplets (10), and specific changes
in gene expression patterns (11, 12). This could be me-
diated directly by PUFAs as ligands of transcription factors,
or indirectly through metabolites of PUFAs or other sec-
ondary events. There is evidence indicating that fatty acids
may regulate gene expression directly. The activity and
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abundance of several nuclear transcription factors, like per-
oxisome proliferator-activated receptors (PPARa/y/g), liver
X receptors (LXRa/b), and sterol regulatory element-
binding proteins (SREBP1/2), have been shown to be reg-
ulated by dietary PUFAs and their metabolites (11, 13).
Cellular stress from cytotoxic agents may result in adap-
tive mechanisms in several cellular compartments, including
endoplasmic reticulum (ER). ER has three main functions:
1) folding, glycosylation, and sorting of proteins to their
proper destination; 2) synthesizing cholesterol and other
lipids; and 3) maintenance of Ca21 homeostasis. Disruption
of any of these processes causes ER stress and activates the
unfolded protein response (UPR). The UPR up-regulates
genes that support adaptation to and recovery from ER
stress as well as initiating apoptotic pathways when damage
is severe. Three transmembrane proteins mediate the UPR
signal across the ER membrane: inositol-requiring enzyme
1 (IRE1), eukaryotic translation initiation factor 2a (eIF2a)
kinase 3 (EIF2AK3/PKR-like ER kinase [PERK]), and acti-
vating transcription factor 6 (ATF6). PERK belongs to a
family of eIF2a kinases that regulates the translational
control during the UPR. Phosphorylation of eIF2a by
PERK leads to attenuation of global protein synthesis, but
promotes translation of certain mRNAs, like activating tran-
scription factor 4 (ATF4) mRNA (14). Downstream targets
of ATF4 are CHOP, GADD34, ATF3, and genes involved in
amino acid metabolism, glutathione biosynthesis, resis-
tance to oxidative stress, and protein secretion. Loss of cy-
clin D1 during ER stress leads to G1 arrest and provides
the cell with an opportunity to restore cell homeostasis
(15). However, prolonged ER stress may cause cell death.
ER stress-induced apoptosis may be mediated by caspase-
12, caspase-9, and caspase-7 (16).
Several links exist between signaling pathways control-
ling the UPR and lipogenesis. Activation of the transcription
factors ATF6 as well as the SREBPs that control cholesterol
and lipid synthesis requires translocation from the ER to
the Golgi followed by cleavage by site-1 protease (S1P)
and site-2 protease (S2P) (17). Also, ER stress may activate
expression of genes involved in cholesterol biosynthesis
(18, 19). Both elevated levels of cholesterol as well as de-
pletion have been shown to induce ER stress (20, 21).
We have previously shown that the human colon cancer
cell lines SW480 and SW620, derived from a primary and a
secondary tumor of the same patient, respectively, were
strongly growth inhibited by docosahexaenoic acid (DHA)
(5). DHA enhanced lipid peroxidation in both cell lines sig-
nificantly, measured as accumulation of the end product
malondialdehyde. The antioxidant vitamin E (a-tocopherol)
completely abolished the increase in malondialdehyde,
without restoring cell growth, demonstrating that the cells
were resistant to lipid peroxidation products. DHA accumu-
lated mainly as triglyceride and cholesteryl ester-enriched
lipid droplets in SW480 and SW620, respectively. The
protein level of the nuclear form of SREBP1 (nSREBP1)
decreased in both cell lines, indicating a possible relation-
ship between disturbances in lipid homeostasis and cell-
cycle arrest. We demonstrate that DHA-treatment of
SW620 cells results in extensive changes in gene expres-
sion patterns at the mRNA level. Early changes include in-
duction of ER stress, as evident from the abundant presence
of phosphorylated eIF2a (eIF2a-P); increase in cytosolic
Ca21; and disturbances in lipid metabolism. Downstream
signaling subsequently results in growth arrest and protein
degradation. Key mediators of ER stress, eIF2a-P, as well as
ATF4 were also induced by eicosapentaenoic acid (EPA),
but not by oleic acid (OA) treatment.
MATERIALS AND METHODS
Cell culture and fatty acid treatment
Human colon adenocarcinoma cell line, SW620, was obtained
from American Type Culture Collection (Rockville, MD). Cells
were cultured in Leibovitzʼs L-15 medium (Cambrex, BioWhittaker,
Walkersville, MD) supplemented with L-glutamine (2 mM), FBS
(10%), and gentamicin (45 mg/l) (complete growth medium)
and maintained in a humidified atmosphere of 5% CO2: 95%
air at 37°C. Stock solutions of DHA, EPA, and OA in ethanol
(Cayman Chemical, Ann Arbor, MI) were stored at 220°C and
diluted in complete growth medium before experiments (final
concentration of ethanol , 0.025% v/v).
RNA isolation
Seeded in 75 cm2 flasks were 1.5 3 106 cells. After 8 h, com-
plete growth medium supplemented with DHA (70 mM) or an
equal volume of ethanol (control) was added, and cells were in-
cubated for 12, 24, and 48 h. Cells were harvested by scraping in
ice-cold phosphated buffered saline (PBS) and stored at 280°C.
Total RNA was isolated using the High Pure RNA Isolation Kit
(Roche, Mannheim, Germany) according to instruction manual.
RNase inhibitor rRNasin (40U/ml, 1 ml) (Promega, Madison, WI)
was added, and RNA was up-concentrated on a speed vac and re-
suspended in RNase free distilled H2O. RNA concentration and
quality were determined using the NanoDrop1000 (NanoDrop
Technologies, Wilmington, DE) and agarose gel electrophoresis.
Gene expression profiling
Five micrograms total RNA was used for cDNA and cRNA syn-
thesis according to the eukaryote expression manual (Affymetrix,
Santa Clara, CA). Detailed gene expression profiling procedure
can be found in supplementary data. cRNA was hybridized to
the Human Genome Focus Array (Affymetrix). Washing and stain-
ing were performed using the Fluidics Station 400 (Midi-Euk2v3
protocol). The arrays were scanned using an Affymetrix GeneChip
GA2500 Scanner, controlled by GeneChip: Operating Software
1.2 (GCOS, Affymetrix). Expression profiling was performed in
triplicates at all time points using RNA from independent bio-
logical replicates. All experiments have been submitted to Array-
Express with accession number E-MEXP-1014.
Statistical analysis of gene expression data
Statistical analysis was performed based on summary expression
measures for each probe set of the GeneChips, using the raw data
(CEL) files and a linear statistical model for background-corrected,
quantile normalized, and log-transformed perfect match values,
performed by the robust multiarray average (RMA) method
(22, 23).
For each transcript, a linear regression model including pa-
rameters representing treatment effects and time effects for the
treatment group was fitted to the RMA expression measures.
Based on the estimated effects, tests for significant differential ex-
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pression due to DHA treatment were performed using moder-
ated t-tests, in which gene-specific variance estimates are replaced
by variance estimates found by borrowing strength from data on
the remaining genes (24).
To account for multiple testing, adjusted P values controlling
the false discovery rate were calculated (25) by inserting the es-
timated value of the proportion of nondifferentially expressed
genes (26). Differentially expressed genes were selected based
on a threshold of 0.05 on the adjusted P values.
Time effect in the control groups were considered negligible
and omitted from the model. Statistical analysis was performed
in R (27), using the packages Limma and affy from Bioconductor
(28). Differentially expressed genes were annotated using the
NetAffx Analysis Centre (http://www.Affymetrix.com) and NMC
Annotation Tool/eGOn V2.0 (http://www.GeneTools.no).
Immunoblot analysis
DHA treatment of cells and preparation of total protein ex-
tracts were performed as described previously (5). Nuclear ex-
tracts for detection of ATF4 were prepared using a Nuclear
extract kit (Active Motif, Belgium) according to manufacturerʼs
instructions. To detect phosphorylated eIF2a, cells were washed
and scraped in ice-cold PBS-1 mM EDTA and pelleted by centri-
fugation. Pellets were lysed in 2 3 packed cell volumes of lysis
buffer on ice for 10 min. Equal amounts of protein were sepa-
rated on 10% precast denaturing NuPAGE gels (Invitrogen,
Carlsbad, CA) and transferred to polyvinylidene difluoride mem-
branes (Millipore, Billerica, MA). The blots were incubated with
the indicated primary and horse radish peroxidase-conjugated
secondary antibodies (DAKO, Carpinteria, CA) and detected by
chemiluminescense using Super Signal West Femto Maximum
Sensitivity Substrate (Pierce, Rockford, IL) and visualized by
Kodak Image Station 4000R (Eastman Kodak Co., Rochester,
NY). Quantification was performed using Kodak Molecular Imag-
ing Software (version 4.0.1). Details about buffers and primary
antibodies can be found in the supplementary data.
Measurement of cytosolic calcium in single cells
Cytosolic free Ca21 in single cells was determined as previously
described (29). In short, cells were incubated for 40 min at 37°C
with a solution of 5 mM fura-2, 0.25% DMSO, and 0.025% Pluronic
F-127 (TefLab, Austin, TX) in HEPES-buffered salt solution
(HSS). Cells were then washed once and incubated in 400 ml
HSS. Applications to cells were done by injecting 100 ml of ago-
nist into the well. Ca21 imaging and registration software has
been developed by Rotnes and Iversen (30). Cytosolic Ca21 con-
centration was calculated using the equation: [Ca21] 5 Kdb(R 2
Rmin)/(Rmax 2 R) (31). Fluorescence data were analyzed using
the program LICS (32).
Analysis of total cholesterol levels
Seeded in 175 cm2 flasks were 4 3 106 cells. The following day,
medium was replaced with complete growth medium supple-
mented with DHA (70 mM) or medium with equal volume of
ethanol and harvested after 3, 6, 12, 24, and 48 h incubation.
Cells were harvested by trypsination and resuspended in PBS to-
gether with floating cells collected by centrifugation. The cell sus-
pension was counted using a Coulter Counter (Beckman Coulter,
Fullerton, CA) and an aliquot of 4 3 106 cells was collected by
centrifugation. Lipids were extracted from the cell pellet (33)
using chloroform-methanol-water (1:2:0.8 v/v/v). Total choles-
terol levels (cholesteryl ester and free cholesterol) in the lipid ex-
tracts were determined using the Amplex Red Cholesterol Assay
Kit (Invitrogen) according to the instruction manual. Data were
expressed as mg cholesterol/mg protein.
Analysis of cholesterol and cholesteryl ester synthesis
Seeded in 175 cm2 flasks were 4 3 106 cells. The following day,
medium was replaced with complete growth medium supple-
mented with DHA (70 mM) or with equal volume of ethanol (con-
trol) and incubated for 24 h. Cells were then incubated with
complete growth medium containing 14C-acetate (1.2 mCi/ml)
and DHA (70 mM) or ethanol (control cells) for 4 and 6 h. Cells
(12 3 106) were harvested by trypsination, and cellular lipids
were extracted with chloroform/methanol according to a method
modified after Bligh and Dyer (33). Lipids were separated by thin
layer chromatography using hexane/diethyl ether/acetic acid
(70:30:1, v/v/v) and lipids were visualized using iodine vapor.
Lipid fractions were solubilized in Insta-gel plus (Perkin Elmer)
before counting. Data were expressed as incorporation of 14C-
acetate into cholesterol/cholesteryl ester (cpm/mg protein).
RESULTS
Growth inhibition by DHA through ER stress and growth
arrest signaling
The human colon cancer cell line SW620 is strongly
growth-inhibited by DHA. Between 72 h and 144 h, essen-
tially no growth could be observed after treatment with
70 mM DHA (5). Although growth retardation was modest
after 24 h, [3H]thymidine incorporation was reduced 30–
40% in SW620 cells already by 12 h, while no effect was
observed after 6 h (data not shown).
We demonstrate that complex gene networks and cell
signaling pathways are affected at the mRNA level after
DHA treatment in SW620 cells (Fig. 1 and Table 1). The
number of transcripts differentially expressed increased
from 12 to 24 h of DHA treatment [up-regulated: 839
(12 h) vs. 1157 (24 h); down-regulated: 1066 (12 h) vs.
1222 (24 h)], while the number decreased at 48 h (up-
regulated: 288; down-regulated: 267). The fold change of
transcript levels after DHA treatment ranged from 1.2 to
24, the majority of which being toward the lower end.
Transcripts could be classified into several functional cate-
gories after annotation as shown in Table 1 and outlined
in later discussion. More comprehensive information on
changes in gene expression is found in the supplemen-
tary Table I. Early changes include induction of ER stress
and UPR.
The protein levels of selected target genes were mea-
sured in SW620 cells after DHA treatment. Importantly,
we demonstrate that an abundant amount of eIF2a-P is
found as early as 3 h after DHA treatment, preceding the
activation of ATF4 and HMOX1 (Fig. 2A). Phosphorylation
of eIF2a is considered a hallmark of the UPR and ER stress
and leads to attenuation of global protein synthesis, but
promotes translation of certain mRNAs, like ATF4 mRNA
(15). In accordance with this, ATF4 is up-regulated here
both at the mRNA and protein level (Table 1 and Fig. 2A).
Downstream targets of ATF4, ATF3, and genes involved in
amino acid metabolism (ASNS), glutathione biosynthesis,
resistance to oxidative stress (HMOX1), and protein secretion
are up-regulated at the mRNA level and (when examined)
at the protein level (Fig. 2A, Table 1 and supplementary
Table I). Also, ATF6, PERK, and X-box binding protein 1
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(XBP1), a downstream target of ATF6, are up-regulated at
mRNA level in SW620 cells (Table 1). XBP1 regulates a
subset of ER-resident chaperones that are essential for pro-
tein folding, maturation, and degradation in the ER (34).
Cyclin D1 is significantly down-regulated both at mRNA
and protein level (Table 1, Fig. 2B, C), probably mediated
by phosphorylated eIF2a that has been shown to attenuate
cyclin D1 translation and cause cell-cycle arrest (G1 phase)
in response to prolonged ER stress (15). mRNA for GADD34,
a subunit in phosphorylated eIF2a phosphatase, is up-
regulated in SW620 cells, possibly explaining in part the de-
crease in phosphorylated eIF2a at 12 h and later (Fig. 2A).
Induction of the UPR is initiated through dissociation of
PERK from the ER-resident chaperone BiP/GRP78 that
engages in numerous complexes (35). The protein level of
BiP remained constant at all time points (data not shown).
Treatment of SW620 cells with the ER stress inducers tuni-
camycin (1 mg/ml) and thapsigargin (0.2 mM) for 6 h,
caused a marked down-regulation of cyclin D1 compared
with control (results not shown). These results confirm
that ER stress in SW620 cells leads to down-regulation of
cyclin D1.
Induction of ER stress and UPR is followed by disruption
of protein folding and destruction of defective proteins by
ER-associated degradation. Several members of the molec-
ular chaperone Hsp40, Hsp70, and Hsp90 families were
up-regulated at the mRNA level (Table 1 and supplemen-
tary Table I). Hsp70 was also found to be up-regulated at
the protein level (Fig. 2A).
Several transcripts belonging to the ubiquitin/proteasome
system were up-regulated (Table 1 and supplementary Ta-
ble I). The proteasome family of proteins is responsible for
the degradation of damaged and short-lived proteins. In
SW620, mRNA for 27 out of 34 subunits (present on the
Human Genome Focus array) of the proteasome 26S were
up-regulated. The proteasomal subunit proteasome 26S
subunit, non-ATPase, 1 (PSMD1)/Rpn2 was significantly
increased relative to control at protein level (Fig. 2A).
Also, the mRNA level of sequestosome 1 (SQSTM1), which
serves as a storage place for ubiquitinated proteins in the
cytoplasm, was up-regulated at all time points in SW620
cells (Table 1). These results support the view that the
ER stress response initiated by DHA causes extensive
changes in protein homeostasis in these cells.
We have previously shown that EPA has an antiprolifera-
tive effect on SW620 cells, although to a lesser extent than
DHA, while OA has no effect (5). Key mediators of ER
stress and UPR were also induced at protein level by
EPA, but not OA, at equal molar concentrations (Fig. 3).
DHA-treatment (70 mM) of SW620 cells induced phos-
phorylation of eIF2a already after 3 h (Fig. 2A), while a
weaker response is observed after treatment with EPA
(70 mM) or half molar concentrations of DHA (35 mM)
first at 24 h (Fig. 3). A similar time- and concentration-de-
pendent response is also observed for the induction of
ATF4 (Fig. 3). Also, EPA (70 mM) and DHA (35 and 70
mM) reduced the level of cyclin D1 after 24 h (Fig. 2B, C
and Fig. 3). After 6 h, only DHA (70 mM) reduced the level
of cyclin D1 significantly, whereas DHA (70 mM) and EPA
(70 mM) both reduced cyclin D1 substantially and with com-
parable effects after 24 h. OA did not affect the prolifera-
tion of SW620 cells. However, OA reduced the level of
cyclin D1 after 24 h, although to a much lesser extent
(Fig. 3). This reflects the differences in the antiproliferative
effect between the PUFAs observed earlier.
DHA induces antioxidant response
PUFAs are subject to lipid peroxidation, thus causing
oxidative stress. Some cell lines that have weak antioxidant
defense are highly sensitive to n-3 PUFAs for this reason
(36). However, SW480 and SW620 cell lines display little
sensitivity to lipid peroxidation products (5). Activated
PERK phosphorylates nuclear factor (erythroid-derived
2)-like 2 (Nrf2) (up-regulated in SW620) (Table 1) that
Fig. 1. Docosahexaenoic acid (DHA) induces endo-
plasmic reticulum (ER) stress in SW620 cells. Diagram
showing transcripts found to be affected by DHA treat-
ment in SW620 cells by gene expression analysis (up-
regulated, pink; down-regulated, blue) in the main
pathways of ER stress signaling. Three transmembrane
proteins mediate the unfolded protein response
(UPR) across the ER membrane after dissociation
from BiP, activating transcription factor 6 (ATF6),
PERK, and inositol-requiring enzyme 1 (IRE1). Each
of these proteins represents distinct pathways of the
ER stress response.
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TABLE 1. Functional categories of differentially expressed transcripts affected in SW620 cells treated with docosahexaenoic acid (DHA) (70 mM) at
time points indicated
SW620 Fold Change
Gene Symbol Affymetrix ID Refseq NCBI ID Description 12 h 24 h 48 h
ER Stress Response
ATF3 202672_s_at NM_001030287 Activating transcription factor 3 3.7 4.1 3.1
NM_001040619
NM_001674
NM_004024
ATF4 200779_at NM_001675 Activating transcription factor 4 2.1 2.0 1.6
NM_182810
ATF6 203952_at NM_007348 Activating transcription factor 6 1.3 1.2 —
EIF2S1 201142_at NM_004094 Eukaryotic translation initiation factor 2-a NC NC NC
GADD34 37028_at NM_014330 Growth arrest and DNA-damage-inducible 34 6.3 3.9 —
NRF2 201146_at NM_006164 Nuclear factor E2-related factor 2.0 1.8 —
PERK 218696_at NM_004836 PKR-like ER kinase 1.4 2.0 —
VCP 208649_s_at NM_007126 Valocin containing protein 1.9 1.6 —
XBP1 200670_at NM_001079539 X-box binding protein 1 2.0 1.8 —
NM_005080
Chaperones/Protein Folding/UPR Response
DNAJB1 200666_s_at NM_006145 DnaJ homolog, subfamily B, member 1 8.0 4.1 —
HMOX1 203665_at NM_002133 Heme oxygenase (decycling) 1 24.0 10.6 5.7
HSPA1A/B 200800_s_at NM_005345 Heat shock 70 kDa protein 1A/B 17.8 9.8 5.1
NM_005346
HSPA1B 202581_at NM_005346 Heat shock 70 kDa protein 1B 9.8 6.5 3.1
HSP47 207714_s_at NM_001235 Heat shock protein 47 4.4 1.8 —
Ubiquitine/Proteasome
PSMD1/RPN2 211198_s_at NM_002807 Proteasome 26S subunit, non-ATPase, 1 2.2 2.2 —
SQSTM1 213112_s_at NM_003900 Sequestosome 1 7.7 6.7 5.0
SQSTM1 201471_s_at NM_003900 Sequestosome 1 6.7 7.3 3.9
Ca21 Homeostasis
CAMLG 203538_at NM_001745 Calcium modulating ligand 1.9 1.9 —
CAPN2 208683_at NM_001748 Calpain 2, large subunit 1.3 1.8 1.4
CAPN7 203356_at NM_014296 Calpain 7 — 1.5 —
IP3R1 203710_at NM_002222 Inositol 1,4,5-triphosphate receptor, type 1 1.5 2.2 1.4
IP3R3 201189_s_at NM_002224 Inositol 1,4,5-triphosphate receptor, type 3 — — 1.3
Antioxidants/Oxidative Stress
CAT 201432_at NM_001752 Catalase — 21.4 —
GCLC 202922_at NM_001498 Glutamate-cysteine ligase, catalytic subunit 1.6 1.3 —
GCLM 203925_at NM_002061 Glutamate-cysteine ligase, modifier subunit 3.7 3.5 2.0
HMOX1 203665_at NM_002133 Heme oxygenase (decycling) 1 24.0 10.6 5.7
SOD1 200642_at NM_000454 Superoxide dismutase 1 1.5 1.6 —
TXNRD1 201266_at NM_003330 Thioredoxin reductase 1 3.2 2.9 1.9
NM_182729
NM_182742
NM_182743
Cell Cycle/Apoptosis
BAG3 217911_s_at NM_004281 BCL2-associated athanogene 3 9.9 5.4 —
CASP4 209310_s_at NM_001225 Caspase 4 1.6 2.9 —
NM_033306
NM_033307
CASP7 207181_s_at NM_001227 Caspase 7 1.6 2.1 —
NM_033338
NM_033339
NM_033340
CCND1 208712_at NM_053056 Cyclin D1 21.7 22.0 —
TRIB3 218145_at NM_021158 Tribbles homolog 3 (Drosophila) 7.4 6.5 3.3
Cholesterol Biosynthesis, Uptake, Metabolism, and Transport
CAV1 203065_s_at NM_001753 Caveolin 1, caveolae protein, 22 kDa 21.5 21.4 —
DHCR24 200862_at NM_014762 24-dehydrocholesterol reductase 21.6 21.7 —
DHCR7 201791_s_at NM_001360 7-dehydrocholesterol reductase 21.6 21.5 —
FDPS 201275_at NM_002004 Farnesyl diphosphate synthase 21.3 21.2 —
HMGCR 202539_s_at NM_000859 3-hydroxy-3-methylglutaryl-CoA reductase NC NC NC
LDLR 202068_s_at NM_000527 Low density lipoprotein receptor 2.4 2.4 —
LSS 202245_at NM_002340 Lanosterol synthase 21.3 —
NPC1 202679_at NM_000271 Niemann-Pick disease, type C1 3.0 4.5 1.9
NPC2 200701_at NM_006432 Niemann-Pick disease, type C2 1.5 1.5
OSBP 201800_s_at NM_002556 Oxysterol binding protein 1.4 1.4 —
PMVK 203515_s_at NM_006556 Phosphomevalonate kinase -1.3 21.8 —
SREBP2 201247_at NM_004599 Sterol regulatory element binding protein 2 NC NC NC
TM7SF2 210130_s_at NM_003273 Transmembrane 7 superfamily member 2 21.4 21.9 —
VLDLR 209822_s_at NM_001018056 Very low density lipoprotein receptor 1.6 1.6 —
NM_003383
NC, no change; UPR, unfolded protein response.
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promotes transcription of genes involved in redox homeo-
stasis, which contributes to survival of ER stress induced in
mammalian cells. Oxidative stress-related genes that were
found to be up-regulated in SW620 cells included thio-
redoxin reductase 1 (TXNRD1), superoxide dismutase 1
(SOD1), HMOX1, glutamate-cysteine ligase modifier
(GCLM), and glutamate-cysteine ligase catalytic subunits,
(GCLC) indicating a disturbance in the redox balance
(Fig. 1 and Table 1). HMOX1, GCLM, and TXNRD1 are
downstream targets of Nrf2 (14). HMOX1 displays a 24-fold
induction at 12 h and is also strongly induced at the pro-
tein level (Fig. 2A and Table 1). HMOX1 catabolizes cellu-
lar heme to biliverdin, which is reduced to bilirubin, both
being very potent cytoprotective antioxidants (37). How-
ever, knockdown of HMOX1 by siRNA did not result in in-
creased DHA-sensitivity in SW620 cells (data not shown),
supporting our previous findings that lipid peroxidation
is not the key mediator of cytotoxicity.
Effect of DHA treatment on Ca21 homeostasis and genes
involved in apoptosis
ER stress-induced depletion of Ca21 stores or dysreg-
ulation of Ca21 homeostasis may trigger apoptosis. We
found that mRNA for a large number of genes involved
in Ca21 homeostasis was changed, mostly up-regulated,
after DHA treatment in SW620 cells. Thus, transcripts for
the inositol 1,4,5-triphosphate receptors (IP3R1 and 3)
were up-regulated, indicating a release of Ca21 regulated
by these receptors (Table 1 and supplementary Table I).
In agreement with this, treatment with DHA (70 mM) for
12–48 h resulted in an increase in cytosolic Ca21 concen-
tration (Fig. 4A). Cytosolic [Ca21] is mainly regulated by
means of transport across cell membranes (e.g., the plasma
and ER membranes). Thapsigargin is a specific inhibitor of
a Ca21 ATPase, which pumps Ca21 into ER. The rate of
[Ca21] increases in cytosol after addition of thapsigargin
thus reflects Ca21 turnover in ER, the main intracellular
Fig. 2. Analysis of proteins involved in ER stress signaling and UPR. A: Western blot analysis of proteins
involved in ER stress signaling and UPR from total cell extracts (except for ATF4: nuclear extracts; eIF2a:
cytoplasmic extracts) of SW620 cells treated with DHA for indicated time periods (h). Controls were har-
vested at all time points; only the 24 h control (C means control) is shown. B: Western blot analysis of cyclin
D1 from total extracts of SW620 cells treated or not treated (controls) with DHA for the indicated time
periods (h). C: Quantification of cyclin D1 Western blots in B [DHA treated cells (gray bars) compared with
controls (black bars)]. Results were verified in three independent experiments; one representative blot is
shown. b-actin (total extracts), lamin C (nuclear extacts), or total eIF2a was used as a control for equal
protein loading. The blots were quantified and protein band intensities normalized relative to loading con-
trol. The adjusted band intensities from the DHA and control membranes were then normalized relative to
the 24 h control band, present at all membranes, to adjust for differences in signal intensities between the
membranes. The numbers under the blots represent mean fold change (SD) of DHA samples relative to
control at the indicted time points for three independent experiments. * Significantly different from control
(Studentʼs t-test, P , 0.05).
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Ca21 store. In SW620 this effect was apparent first after 48
h DHA incubation (average [Ca21] increase 267nM vs.
187nM in control). The time course of these registrations
is shown in Fig. 4B.
A Ca21 signal after agonist-binding to a G protein cou-
pled receptor often displays two phases: an initial peak re-
sponse, which is due to release from intracellular stores;
and a prolonged phase, which is attributable to Ca21 entry
through the plasma membrane due to emptying of intra-
cellular Ca21 stores (“capacitative” or store operated Ca21
influx). This Ca21 entry is abolished when free extracellu-
lar [Ca21] is chelated by ethylene glycol tetraacetic acid
(EGTA). We find that ATP is an agonist that releases a
two-phasic Ca21 signal in most SW620 cells. Incubation
with DHA for 12 h and more seemed to accentuate the sec-
ond phase Ca21 elevation in SW620 cells (Fig. 4C, Table 2),
whereas the first peak response was virtually unchanged.
The time course of the registrations from ATP-stimulated
SW620 cells are shown in Fig. 4C. When EGTA was added
to SW620 cells treated with DHA for 24 h and then stimu-
lated with ATP, we found that the second phase Ca21 eleva-
tion was abolished (Fig. 4D, Table 3). The elevation in
prolonged Ca21 signal in DHA-treated cells after ATP stim-
ulation can therefore be ascribed to Ca21 entry, probably of
the capacitative type.
Disturbances in the Ca21 pool of ER activate calpain in
the cytosol, which then converts ER-localized procaspase
12 to caspase 12 (38). Calpain 7 and a large subunit of
calpain 2 as well as the ER stress-related caspases (caspase
4 and 7) were up-regulated in SW620 cells (Table 1). The
proapoptotic members of the Bcl-2 family, BAD and BIK,
were down-regulated, while BID was up-regulated (SW620).
BCL2-associated athanogene 3 (BAG3), known to partici-
pate in regulation of apoptosis, was up-regulated 9.9-fold
in SW620 cells after 12 h incubation with DHA. Also, the
proapoptotic factor Tribbles homolog 3 (TRIB3), known
to be induced by ER stress through the PERK-ATF4-CHOP
pathway, was up-regulated at all time points (Table 1) (39).
The protein level of active caspase 7 was found to increase
with time in SW480 cells, while not detected in SW620 cells
(data not shown).
Effect of DHA on cellular cholesterol and
cholesterol metabolism
We have previously shown that treatment of SW480
and SW620 with DHA leads to accumulation of numerous
large lipids droplets, mainly containing triglycerides in
SW480 and cholesteryl esters in SW620 (5). However, an
increase in cholesteryl esters was also seen in SW480. The
formation of lipid droplets is probably induced by DHA,
since they are highly enriched in this PUFA. To examine
whether this accumulation of esterified cholesterol was
compensated for by increased total cholesterol levels, we
measured cellular cholesterol content after DHA treatment.
No significant differences in total cholesterol were found at
3–24 h when comparing control and DHA-treated cells
Fig. 3. ER stress signaling and UPR in response to n-3 polyunsaturated fatty acids (PUFAs) and oleic acid
(OA). Western blot analysis of proteins involved in ER stress signaling and UPR (ATF4: nuclear extracts;
cyclin D1, eIF2a: cytoplasmic extracts) in SW620 cells treated with complete growth medium supplemented
with either OA (70 mM), DHA (35 mM), eicosapentaenoic acid (EPA, 70mM), or ethanol (control media, C)
for 6 and 24 h. b-actin (cytoplasmic extracts), lamin C (nuclear extracts), or total eIF2a was used as a control
for equal protein loading. One representative blot is shown. The blots were quantified and intensities
normalized relative to loading control. The numbers under the blots represent mean fold change (SD) rel-
ative to control for three independent experiments. * Significantly different from control (Studentʼs t-test,
P , 0.05).
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(data not shown). A slight, but significant increase in total
cholesterol levels in DHA-treated cells was observed at 48 h
(31.28 6 1.29 (control) vs. 38.75 6 3.39 mg cholesterol/
mg protein, P , 0.05). These results may indicate that
cholesterol available for organelles is reduced due to de-
position in lipid droplets.
From the gene expression data, it was apparent that sev-
eral genes encoding proteins involved in cholesterol bio-
synthesis were down-regulated at the mRNA level in
DHA-treated SW620 cells (Table 1). These include 7- and
24-dehydrocholesterol reductase (DHCR7, DHCR24), far-
nesyl diphosphate synthase (FDPS), phosphomevalonate
TABLE 2. Ca21 registrations in SW620 cells pretreated with DHA (70 mM) at time points indicated: SW620 cells
stimulated with ATP, 1 mM
Pretreatment # Cells (Responding Cells, %) Maximal [Ca21] Increase, nM Decline of the Response
None (control) 120 (56) 190 (6 13.2) 1.64 (6 0.06)
DHA 6 h 110 (53) 196 (6 10.8) 1.66 (6 0.16)
DHA 12 h 107 (55) 226 (6 15.9)a 1.39 (6 0.06)a
DHA 24 h 94 (51) 201 (6 18.4) 1.27 (6 0.09)b
DHA 48 h 97 (45) 198 (6 21.1) 1.23 (6 0.04)b
After 30 s of [Ca21] registration ATP (1mM) (Sigma-Aldrich) or vehicle was added. Maximal [Ca21] increase is
calculated as difference between baseline and peak [Ca21] in the responding cells. The decline of the response is
quantified as the ratio between peak [Ca21] and [Ca21] at the end of the registration (180 s). Registrations are
depicted in Fig. 4C. The data are presented as means with standard errors (6 SEM).
a Statistically significant difference from control (P , 0.05).
b Statistically significant difference from control (P , 0.01).
Fig. 4. Cytosolic Ca21 release after DHA treatment. Registrations of cytosolic Ca21 in DHA-treated SW620 cells. A: DHA treatment in-
creases the basic cytosolic Ca21 level in SW620 cells. SW620 cells were incubated with DHA (70 mM) for various time periods as indicated.
Average Ca21 concentrations in 196–324 cells are shown. Bars indicate SEM values. The average basic cytosolic Ca21 level from each time
period was tested against time 0. Statistically significant difference from control (no treatment): ** P , 0.01. B: DHA treatment affects the
thapsigargin-inhibited Ca21 transport. SW620 cells were incubated with DHA (70 mM) for 48 h as indicated. After 30 s of [Ca21] registration
thapsigargin (5 mM) (Sigma-Aldrich) or vehicle was added (arrow). Average registrations from all cells are shown since virtually all cells
responded. Cytosolic [Ca21] at the end of the registration (180 s) in DHA-treated cells was statistically significant different from control (P,
0.05). C: ATP stimulation causes a prolonged Ca21 signal in DHA-treated cells. SW620 cells were incubated with DHA (70 mM) for various
time periods as indicated. After 30 s of [Ca21] registration ATP (1 mM) was added (arrow). Average registrations from responding cells are
shown. D: Removal of extracellular Ca21 with ethylene glycol tetraacetic acid (EGTA) abolishes the prolonged ATP response in DHA-treated
cells. SW620 cells were incubated with DHA (70 mM) for 24 h. The cells were incubated in a 10 mM HEPES buffer without Ca21, but with
0.1 mM EGTA or in a 10 mM HEPES buffer containing 1.2 mM Ca21 for 10 min before registration. After 30 s of [Ca21] registration, ATP
(1 mM) was added (arrow). Average registrations from responding cells are shown.
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kinase (PMVK), 3b-hydroxysterol D14-reductase (TM7SF2)
(12, 24 h), and lanosterol synthase (LSS) (12 h). However,
some transcripts involved in cholesterol uptake and intracel-
lular cholesterol transport, such as low and very low density
lipoprotein receptor (LDLR, VLDLR), the Niemann-Pick
C1 protein (NPC1), NPC2, and the oxysterol binding pro-
tein (OSBP), were found to be up-regulated in SW620 cells
after DHA-treatment (Table 1). NPC1 protein levels were in
addition analyzed by Western blot and were increased in
DHA-treated cells compared with control at 24 h (Fig. 5A).
TABLE 3. Ca21 registrations in SW620 cells pretreated with DHA (70 mM) at time points indicated: SW620 cells
stimulated with ATP, 1mM
Pretreatment # Cells Baseline [Ca21], nM Maximal [Ca21] Increase, nM Decline of the Response
None (control) 103 123 (6 4.1) 247 (6 10.6) 2.07 (6 0.09)
DHA 24 h 85 141 (6 4.7)a 238 (6 14.1) 1.61 (6 0.07)a
2. EGTA 81 103 (6 3.7)a 259 (6 18.2) 2.51 (6 0.14)a
EGTA, DHA 24 h 73 105 (6 3.8)a,b 227 (6 17.3) 2.11 (6 0.12)a,b
EGTA, ethylene glycol tetraacetic acid. After 30 s of [Ca21] registration ATP (1mM) (Sigma-Aldrich) or vehicle
was added. Maximal [Ca21] increase is calculated as difference between baseline and peak [Ca21] in the responding
cells. The decline of the response is quantified as the ratio between peak [Ca21] and [Ca21] at the end of the
registration (180 s). Registrations are depicted in Fig. 4D. The data are presented as means with standard errors
(6 SEM).
a Significantly different from control (P , 0.05).
b Significantly different from DHA 24 h (÷ EGTA) (P , 0.001).
Fig. 5. Changes in cholesterol metabolism induced by DHA. A: Western blot analysis of HMGCR,
mSREBP2, and NPC1 protein levels in total protein extracts from SW620 cells treated with DHA for the
indicated time periods (h). Controls were harvested at all time points; only 24 h control is shown for
mSREBP2 and NPC1. For HMGCR, controls are shown for all time points. b-actin was used as a control
for equal protein loading. One blot, representing three independent experiments, is shown. The blots were
quantified and protein band intensities normalized relative loading control. The actin adjusted band inten-
sities from the DHA and control membranes were further normalized relative to the 24 h control band,
present at all membranes, to adjust for differences in signal intensities between the membranes. The num-
bers under the blots represent mean fold change (with SD) of DHA samples relative to control at indicted
time points for three independent experiments. * Significantly different from control (Studentʼs t-test, P ,
0.05). B: Alterations in HMGCR and mSREBP2 protein levels in control (baseline) and DHA treated cells at
the indicated time periods. The plots show the mean value of the actin adjusted band intensitites normalized
relative to the 24 h control band for DHA treated cells (gray bars) and control cells (black bars). The data
represent the mean and SD of three independent experiments. * Significantly different from control (Stu-
dentʼs t-test, P , 0.05).
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Since several of the differentially expressed transcripts
listed above are regulated by sterol regulatory element bind-
ing protein 2 (SREBP2), the protein levels of mSREBP2
(mature) and pSREBP2 (precursor) were analyzed by
Western blot. An increase in mSREPB2 levels was observed
in control and DHA-treated cells over the time period
assayed, but DHA-treated cells displayed higher levels of
mSREBP2 compared with control cells at all time points
(Fig. 5A, B). The level of pSREBP2 was unchanged in
SW620 control cells at all time points, while a slight decrease
was observed after 48 h treatment with DHA (data not
shown). We also analyzed the level of the rate-limiting
enzyme in cholesterol biosynthesis, 3-hydroxy-3-methylglu-
taryl-CoA reductase (HMGCR) by Western blot after DHA
treatment. The protein levels of HMGCR in DHA-treated
and control cells were similar at 3 and 6 h. At 12–48 h,
the HMGCR protein levels were reduced in controls, while
the protein level in DHA-treated cells increased slightly
(Fig. 5A, B).
To investigate de novo synthesis of cholesterol in DHA-
treated cells, the incorporation of 14C-acetate into choles-
terol and cholesteryl esters was measured after treating the
cells with DHA for 24 h. The amount of 14C-acetate incor-
porated into cholesterol in DHA treated cells was slightly,
but significantly lower relative to control at 4 h; a similar
trend, although not significant was seen after 6 h (Fig. 6).
The amount of 14C-acetate incorporated into cholesteryl
esters in DHA treated cells was reduced by approximately
60% relative to control at both time points (Fig. 6).
DISCUSSION
Exploring how dietary factors interact with and modu-
late signaling pathways to promote or counteract cancer
development and progression constitutes a major chal-
lenge. The purpose of the present study was to examine
whether n-3 PUFAs like DHA exert their cytotoxicity by
changing gene expression patterns and signaling pathways
regulating cell growth. We found that ER stress is estab-
lished already after 3 h treatment with DHA, as demon-
strated by increased levels of phosphorylated eIF2a, a
hallmark of ER stress. Phosphorylation of eIF2a adapts
cells to various conditions of stress by attenuation of pro-
tein synthesis. We found that the n-3 PUFAs DHA and EPA,
but not OA, cause phosphorylation of eIF2a, thereby gen-
erally inhibiting translation initiation. This is in agreement
with previous results showing that inhibition of translation
initiation mediates the antiproliferative action of EPA in
NIH 3T3 cells by decreased levels of cyclin D1 (40). In-
creased expression of genes downstream of phosphorylated
eIF2a is mediated through induction of the transcription
factor ATF4 (14). Genes with ATF4 binding sites are in-
volved in restoring ER homeostasis in response to various
stresses (41). Several downstream targets of ATF4 are af-
fected at the mRNA and protein level in our study, indi-
cating that ER stress induced by DHA in SW620 cells is
mediated through the ER-localized PERK pathway. Induc-
tion of the UPR is initiated by dissociation of PERK from
the ER-resident chaperone BiP. However, the protein level
of BiP remained constant at all time points. Pimpl et al.
(42) have reported that transcriptional induction of BiP
rarely leads to increased protein levels of BiP/GRP78, this
being due to increased turnover.
UPR is activated to restore cellular homeostasis and in-
duces transcription of genes encoding proteins that me-
diate ER-associated degradation in response to prolonged
ER stress. A large number of 20S and 26S proteasomal sub-
units were up-regulated in SW620 cells. The proteasome
plays a central role in proteolysis of ubiquitinated proteins
and are responsible for cleaving many regulatory proteins,
like cyclins and members of the NFkB family (43). Pro-
longed ER stress may cause induction of apoptosis. We show
that even though the ER stress-related caspases 4 and 7 are
up-regulated in DHA-treated SW620 cells, active caspase 7
is not detectable. On the other hand, active caspase 7 was
detected in SW480 cells (data not shown). Chen and Istfan
(44) have studied the apoptotic response to DHA in sev-
eral cell lines, among these SW480 and SW620. A DNA lad-
der was observed after incubation with DHA (150 mM) for
24 h in SW480, but not in SW620 cells; this is in accor-
dance with our results. Previously, we were not able to de-
tect apoptosis by the TUNEL-assay in either SW480 or
SW620 (5). This may indicate that the survival threshold
is not exceeded in these cells within the time period as-
sayed and concentration used.
ER is the principal site for protein synthesis and folding,
Ca21 storage and signaling, as well as biosynthesis of fatty
acids and cholesterol. Any perturbation that interferes with
these activities promotes ER stress and initiates the UPR.
We found that DHA treatment mobilizes Ca21 from ER
into the cytosol, in agreement with previous results investi-
gating the effects of n-3 and n-6 PUFAs (40, 45–47), but
the mechanism is not known. Our results indicate that cal-
cium release induced by DHA may be linked to induction
of ER stress. A redistribution of cholesterol from intracel-
lular regulatory compartments like ER to DHA-cholesteryl
Fig. 6. Effect of DHA on incorporation of 14C- acetate into choles-
terol and cholesteryl esters. Amount of 14C-acetate (% of control)
incorporated in cholesterol (black bars) and cholesteryl esters
(gray bars) in SW620 cells treated with DHA for 24 h, and further
coincubated with DHA and 14C-acetate for 4 and 6 h. The mean
and 6 SD from (4 h, n 5 3; 6 h, n 5 2) independent experiments
is displayed. * Significantly different from control (Studentʼs t-test,
P , 0.05).
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ester-enriched lipid droplets (5), causing functional deple-
tion of cholesterol in the ER could potentially lead to ER
stress and Ca21 mobilization, since total cholesterol is not
increased (this work). Harding et al. (21) have shown that
compounds that deplete cellular cholesterol stores acti-
vate an integrated stress response (ISR) by promoting
ER stress.
The observed stabilization of HMGCR, the rate limiting
enzyme in cholesterol biosynthesis, and the increased level
of mSREBP2 observed in DHA-treated SW620 cells, indi-
cate an increased cellular need for de novo synthesized
cholesterol during DHA treatment. Surprisingly, both in-
creased and decreased expression of several SREBP2 tar-
get genes is observed in SW620, despite an increase in
the active transcription factor. Inhibition of transcription
of SREBP2 target genes has previously been associated
with ER stress-induced activation and cleavage of ATF6,
and is mediated by interaction of the two transcription fac-
tors in the nucleus (48). Reduced expression of SREBP2
target genes may result in a decreased ability of the cells
to synthesize new cholesterol, in spite of activated SREBP2.
In line with this, we show that DHA promotes a reduced
de novo synthesis of cholesterol. Surprisingly, we also find
a reduced incorporation of newly synthesized cholesterol
into cholesteryl esters (this work), despite the previous ob-
served accumulation of cholesteryl esters in SW620 cells
treated with DHA (5). This might possibly result from re-
duced turnover of DHA-enriched cholesteryl esters in drop-
lets resulting in accumulation in spite of reduced synthesis.
Recently, a link between molecular chaperones, heat
stress, and cholesterol synthesis was demonstrated (49).
In this work, the chaperone DnaJA4 (DnaJ/Hsp40) was
identified as a novel SREBP target gene that can be turned
on under conditions of low sterol availability and heat
shock. They postulated that SREBP-regulated chaperones
may function as effectors linking heat-shock response and
the maintenance of membrane components. Also, Lee
and Ye (18) have shown that both hypotonic conditions
and thapsigargin induced ER stress in CHO-7 cells leads
to activation of SREBP2, while no increase in cholesterol
synthesis was observed.
The reasons why SREBP2 target genes are regulated dif-
ferently, and consequences thereof, remain to be investi-
gated in our system.
Up-regulation of transcripts involved in cellular uptake
and intracellular transport of cholesterol, like LDLR,
VLDLR, NPC1/NPC2, and OSBP in SW620 cells treated
with DHA, also suggests an increased demand for intracel-
lular cholesterol. A recent report indicates that DHA treat-
ment inhibits transport of exogenous cholesterol from the
plasma membrane to the ER by an unknown mechanism
in CaCo2 colon cancer cells (50). In addition, a study on a
panel of colon carcinoma cell lines revealed a deficiency of
the LDLR in SW480 cells, indicating a dependency on
endogenous cholesterol biosynthesis (51). This would
probably also apply to the SW620 cell line, which is estab-
lished from a metastasis derived from the primary SW480
tumor. Reduced de novo cholesterol synthesis and inhi-
bition of transport of exogenous cholesterol to the ER
pool, in combination with increased cholesterol esteri-
fication as observed earlier, may lead to depletion of cho-
lesterol in the ER. This may be an important factor
contributing to the observed prolonged ER stress that
may cause growth inhibition and eventually cell death.
In vitro studies suggest that pharmacological activation
of the UPR can alter the sensitivity of tumor cells to che-
motherapeutic agents (52). Understanding how common
dietary chemicals like DHA affect gene expression and sig-
naling pathways in tumor cells may reveal possible treat-
ment strategies that may be targeted and possibly enhance
the impact of conventional therapy.
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SUPPLEMENTARY EXPERIMENTAL PROCEDURES 
Gene expression profiling – detailed method 
Synthesis of cDNA and biotinylated cRNA was performed according to the eukaryote 
expression manual provided by Affymetrix. In brief, 5 μg total RNA from the SW620 cell 
line was subjected to double-stranded cDNA synthesis using a T7-oligo(dT)24-primer 
(Affymetrix, Santa Clara, CA) and the SuperScript™ Double-Stranded cDNA Labeling Kit 
(Invitrogen, Carlsbad, CA). After clean up (GeneChip Sample Clean Up Module, 
Affymetrix), all the prepared cDNA was used for in vitro transcription using Enzo BioArray 
HighYield RNA Transcript Labeling kit (Enzo, Farmingdale, NY). 10 μg fragmented cRNA 
were hybridized to the Human Genome Focus Array (midi format, Affymetrix) containing 
probe sets for 8500 of the best characterized human genes. Hybridization and 
washing/staining were performed using the Hybridization oven 640 and Fluidics Station 400 
(Midi-Euk2v3 protocol). Staining was performed using Streptavidin, R-phycoerythrin 
conjugate (SAPE, Molecular Probes, Eugene, Oregon) and biotinylated anti-streptavidin 
antibody (Vector Laboratories, Burlingame, CA). The arrays were scanned using an 
Affymetrix GeneChip GA2500 Scanner, controlled by GeneChip Operating Software 1.2 
(GCOS, Affymetrix).  
Statistical analysis of gene expression data - comment 
First, a model was fitted that included time effects for both the DHA-treated and control 
groups. However, the time effects in the control group turned out to be negligible, and these 
effects were omitted from the model.  
Antibodies
Primary antibodies detecting the following proteins were used to probe the membranes; 
HSP70 and HMOX1 (all mouse monoclonal antibodies, Stressgen, Victoria, BC, Canada), 
ATF4 (rabbit polyclonal antibody), HMGCR and lamin (goat polyclonal antibodies) (all from 
Santa Cruz Biotechnology, CA), Cyclin D1 (mouse monoclonal antibody, Cell Signaling 
Technology, Danvers, MA), RPN2 (mouse monoclonal), active CASP7, NPC1 and SREBP2 
(all three rabbit polyclonal antibodies, all four from Abcam, Cambridge, UK). 
Phosphorylation of eIF2D was assayed using an antibody recognizing phosphorylated eIF2D
(Serine 51, Cell Signaling Technology). The membranes were also probed for total eIF2D
(Cell Signaling Technology) as a control after stripping the membrane in Restore Western 
blot Stripping buffer (Pierce, Rockford, IL). All blots were reprobed with E-Actin (Abcam) as 
a loading control. Membranes were probed with horseradish peroxidase (HRP)-conjugated 
secondary antibodies (DAKO, Carpinteria, CA) for one hour at room temperature. 
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Is not included due to copyright 

Paper III
 
Is not included due to copyright 

Errata

Errata list
 
Page 3 (line 5) 
Current sentence: 
ATF  activation transcription factor  
Corrected to: 
ATF  activating transcription factor  
 
Page 5 (line 5) 
Current sentence: 
PPAR peroxisome proliferators-activated receptor 
Corrected to: 
PPAR peroxisome proliferator-activated receptor 
 
Page 6 (line 3) 
Current sentence: 
…the Norwegian professor Notevarp 
Corrected to: 
…the Norwegian Professor Notevarp 
 
Page 10 (chapter 1.2, line 8) 
Current sentence: 
The type of fat consumed has changed towards an increase in saturated fat (especially animal fat and n-6 PUFA 
rich oils)… 
Corrected to: 
The type of fat consumed has changed towards an increase in saturated fat (especially animal fat) and n-6 PUFA 
rich oils… 
Page 11 (line 9) 
Current sentence: 
Feeding farm animals with n-3 FA-enriched food have resulted in production of eggs and milk with increased n-
3 FA content…  
Corrected to: 
Feeding farm animals with n-3 FA-enriched food has resulted in production of eggs and milk with increased n-3 
FA content…  
 
Page 11 (line 8) 
Current sentences: 
Cooking methods also needs to be considered since n-3 PUFAs are highly oxidable resulting in harmful free 
radicals. The n-3 PUFA content in cooked fish might be reduced by as much as 50% (reviewed in 14),  
Corrected to: 
The sentences have been moved to the end of the paragraph.  
Page 11 (line 9) 
Current sentence: 
The n-3 PUFA content in cooked fish might be reduced by as much as 50% (reviewed in 14), and industrial food 
should be prepared using n-3 PUFA rich oils. 
Corrected to: 
Industrial food should be prepared using n-3 PUFA rich oils.  
 
Page 15 (line 1) 
Current sentence: 
Membrains also contain lipid micro domains such as lipid rafts and caveolae which are membrane domains rich 
in cholesterol, sphingolipids and phospholipids.  
Corrected to: 
Membrains also contain lipid micro domains such as lipid rafts and caveolae which are membrane domains rich 
in cholesterol, sphingolipids and phospholipids with saturated fatty acyl chains.   
 
Page 15 (chapter 1.3.5, line 6) 
Current sentence: 
EPA and AA are metabolized by the same enzymes in the three eicosanoid syntehesis pathways… 
Corrected to: 
EPA and AA are metabolized by the same enzymes in the three eicosanoid synthesis pathways… 
  
Page 19 (line 5) 
Current sentence: 
…(reviewed in (50).  
Corrected to: 
…(reviewed in (50)). 
 
Page 19 (chapter 1.4.1, line 5) 
Current sentence: 
…found be important… 
Corrected to: 
…found to be important 
 
Page 20 (last sentence) 
Current sentence: 
This is especially important for breast and prostate cancer since the incidence of these cancers has been 
associated with exposition of such pesticides.  
Corrected to: 
This is especially important for breast and prostate cancer since the incidence of these cancers has been 
associated with exposure of such pesticides.  
Page 24 (line 7) 
Current sentence: 
Some human intervention studies have also been performed, like the studies by Anti, West and Aronson et al 
described above. 
Corrected to: 
Some human intervention studies have also been performed, like the studies by Anti and West et al described 
above. 
 
Page 26 (second paragraph, line 3) 
Current sentence: 
DHA and EPA reduced micro vessel formation in HT-29 colon cancer cells in vitro, as a result of reduced 
expression of COX-2 and vascular endothelial growth factor (VEGF), and reduced PGE2 level. 
Corrected to: 
DHA and EPA reduced the growth of HT-29 colon cancer cells in vitro and reduced expression of COX-2, 
vascular endothelial growth factor (VEGF) and reduced PGE2 level.  
 
Page 27 (chapter 1.5.3, last line) 
Current sentence: 
…(EGF) signaling which to takes place in lipid rafts.  
Corrected to: 
…(EGF) signaling which takes place in lipid rafts.  
 
Page 32 (PERK chapter, line 3) 
Current sentence: 
This leads to inhibition of translation/protein synthesis to relive the protein burden of ER. 
Corrected to: 
This leads to inhibition of translation/protein synthesis to relieve the protein burden of ER. 
 
Page 39 (chapter Apoptosis and n-3 PUFAs, last line) 
Current sentence: 
…(reviewed in (122). 
Corrected to: 
…(reviewed in (122)). 
Page 41 (line 9) 
Current sentence: 
…the cause have not yet been fully established. 
Corrected to: 
…the mechanisms have not yet been fully established. 
 
Page 43 (line 4) 
Current sentence: 
Transcripts for some proteins involved in cholesterol uptake and transport like LDL receptor (LDLR) and 
niemann-pick disease type C1 (NPC1), the latter also at protein level. 
Corrected to: 
Transcripts for some proteins involved in cholesterol uptake and transport like LDL receptor (LDLR) and 
niemann-pick disease type C1 (NPC1) were up-regulated, the latter also at protein level. 
 
Page 43 (line 9) 
Current sentence: 
Taken together, these data imply that the growth inhibitiing effect of DHA on the SW620 cells involves 
induction of ER stress, UPR and changes in Ca2+- and cholesterol homeostasis 
Corrected to: 
Taken together, these data imply that the growth inhibiting effect of DHA on the SW620 cells involves induction 
of ER stress, UPR and changes in Ca2+- and cholesterol homeostasis 
Page 46 (last line) 
Current sentence: 
…induced extensive changes in the expression several genes belonging to a several different molecular 
pathways, in cancer cells.  
Corrected to: 
…induced extensive changes in the expression of several genes belonging to several different molecular 
pathways, in cancer cells.  
 
Page 48 (line 24) 
Current sentence: 
…hence oxidative stress was suggested to be involved in trigging cell death in these cells.  
Corrected to: 
…hence oxidative stress was suggested to be involved in triggering cell death in these cells.  
 
Page 50 (line 3) 
Current sentence: 
…have been implicated in ER stressed-induced apoptosis 
Corrected to: 
…have been implicated in ER stress-induced apoptosis 
 
Page 53 (chapter 4.4, line 5) 
Current sentence: 
…(paper I, table 1, fig. 5) 
Corrected to: 
…(paper I, table1, supplementary table 1, fig. 5) 
 
Page 54 (line 15) 
Current sentence: 
SREBP1 also regulates lipogenesis e.g. trough induction of FAS… 
Corrected to: 
SREBP1 also regulates lipogenesis e.g. through induction of FAS… 
 
Page 56 (4th line from the bottom) 
Current sentence: 
It is important to note that Chen et al used the double DHA concentration… 
Corrected to: 
It is important to note that Chen et al used double the DHA concentration… 
 
Page 58 (line 6) 
Current sentence: 
Unfortunately, several chemotherapeutics is known to activate NFțB… 
Corrected to: 
Unfortunately, several chemotherapies are known to activate NFțB… 
 
Page 60 (6th line from the bottom) 
Current sentence: 
This could help revealing… 
Corrected to: 
This could help reveal… 
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